BROAD-SPECTRUM PROTEOME EDITING WITH AN ENGINEERED BACTERIAL UBIQUITIN LIGASE MIMIC by Ludwicki, Morgan Baltz
BROAD-SPECTRUM PROTEOME EDITING WITH AN ENGINEERED BACTERIAL 
UBIQUITIN LIGASE MIMIC 
 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
 
by 
Morgan Baltz Ludwicki 
August 2019 
 
  
 
 
 
 
 
 
 
 
 
© 2019 Morgan Baltz Ludwicki 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BROAD-SPECTRUM PROTEOME EDITING WITH AN ENGINEERED BACTERIAL 
UBIQUITIN LIGASE MIMIC 
Morgan Baltz Ludwicki, Ph. D.  
Cornell University 2019 
 
Manipulation of the ubiquitin-proteasome pathway to achieve targeted silencing of 
cellular proteins has emerged as a reliable and customizable strategy for remodeling the 
mammalian proteome. One such approach involves engineering bifunctional proteins called 
ubiquibodies that are comprised of a synthetic binding protein fused to an E3 ubiquitin 
ligase, thus enabling post-translational ubiquitination and degradation of a target protein. 
Here, we have designed a panel of new ubiquibodies based on E3 ubiquitin ligase mimics 
from bacterial pathogens that are capable of effectively interfacing with the mammalian 
proteasomal degradation machinery for selective removal of proteins of interest. One of 
these, the Shigella flexneri effector protein IpaH9.8 fused to a fibronectin type III (FN3) 
monobody that specifically recognizes green fluorescent protein (GFP), was observed to 
potently eliminate GFP and its spectral derivatives as well as 15 different FP-tagged 
mammalian proteins that varied in size (27–179 kDa) and subcellular localization 
(cytoplasm, nucleus, membrane-associated, and transmembrane). We further demonstrated 
the modularity and flexibility of IpaH9.8 by redirecting its activity towards the disease 
relevant proteins SHP2, KRas, and ERK2 through the use of binding domains identified in 
literature as well as novel binding domains we isolated using yeast surface display.  
 To demonstrate therapeutically relevant delivery of ubiquibodies, we 
investigated two approaches: endowment of ubiquibodies with a cell-penetrating peptide 
 domain and packaging of mRNA encoding the GFP-specific ubiquibody in bioinspired 
nano-sized complexes. The resulting nanoplexes delivered ubiquibody mRNA in a manner 
that caused efficient target depletion in cultured mammalian cells stably expressing GFP as 
well as in transgenic mice expressing GFP ubiquitously. Lastly, we discuss preliminary 
designs for controlling ubiquibody behavior with spatial and temporal control. Overall, our 
results suggest that IpaH9.8-based ubiquibodies are a highly modular proteome editing 
technology with the potential for pharmacologically modulating disease-causing proteins. 
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CHAPTER 1 – INTRODUCTION 
Natural protein degradation mechanisms 
In response to different environmental cues or as part of their developmental cycle, 
all cells change their cytosolic protein content by modifying the balance between rates of 
protein synthesis and degradation [1, 2]. This feat is accomplished by an integrated 
surveillance system comprised of chaperones and protein degradation machineries that are 
required to maintain protein homeostasis (proteostasis). Two of the major quality 
control pathways responsible for regulating proteostasis are the ubiquitin proteasome 
pathway (UPP) and the lysosomal pathway (LP). In eukaryotic cells, the UPP is the 
primary mechanism through which proteins are tagged and degraded by the 26S 
proteasome [3, 4]. The UPP system is highly conserved in eukaryotes and consists of an 
enzymatic cascade involving, at a minimum, a ubiquitin-activating enzyme (E1), a 
ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase (E3) (Fig. 1.1). In brief, an E1 is 
activated by the addition of a ubiquitin molecule through an ATP-dependent thioester bond 
between the carboxyl-terminal glycine residue in ubiquitin and a cysteine residue in E1. 
Next, the activated ubiquitin molecule is transferred to the active site cysteine residue of an 
E2. Finally, an E3 catalyzes the transfer of the ubiquitin molecule to the e-amino group of 
a lysine residue in the target protein. The attached ubiquitin molecule serves as an acceptor 
for further cycles of ubiquitination, generating a polyubiquitin chain. Each subsequent 
ubiquitin molecule can be attached to any of the seven lysine residues in the preceding 
ubiquitin, creating a diverse variety of polyubiquitin chain topologies that determine 
different protein fates [5] and give rise to the concept of a ubiquitin code [6, 7]. For 
example, polyubiquitin chains linked through Lys48 of ubiquitin are a signal that is 
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recognized by the proteasome, which proteolytically cleaves the tagged protein and yields 
intact ubiquitin molecules and short (7 to 8-residue) peptides. In contrast, chains linked 
through ubiquitin Lys63 serve as signals for the NF-kB activation [8] and DNA repair [9] 
pathways. 
 
 
Figure 1.1 Ubiquitin proteasome pathway.  
The ubiquitin proteasome pathway (UPP) is one of the major quality control pathways 
responsible for regulating proteostasis in mammalian cells. In the UPP, a cascade of 
enzymatic reactions for transferring ubiquitin (Ub) to target proteins is carried out by three 
enzymes: a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a 
ubiquitin ligase (E3). The polyubiquitination of a protein directs it to the 26S proteasome, a 
2.5-MDa molecular machine built from approximately 31 different subunits, which 
catalyzes protein degradation. Figure modified from Lopez-Barbosa et al., 2019. 
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Engineered protein knockdown techniques 
Delineation of protein function has traditionally been investigated at the pre-
translational level through genetic strategies that typically involve disrupting genomic 
DNA or mRNA transcripts, leading to complete or partial elimination of the gene product. 
Such loss-of-function approaches include clustered regularly interspaced short palindromic 
repeat (CRISPR)-Cas systems [10], zinc finger nucleases (ZFNs) [11], transcription 
activator-like effector nucleases [12], RNA interference (RNAi) [13], and antisense 
oligonucleotides (AONs).[14] Although these methods have become commonplace in basic 
research and are showing promise in the treatment of disease [15-20], gene silencing and 
genomic editing strategies are limited by a number of challenges including lack of 
temporal control and unpredictable off-target effects. Other issues include the inability to 
remove essential genes in the case of genome editing and the inability to decrease levels of 
proteins already present within cells, thereby leaving stable, long-lived proteins unaffected 
in the case of gene silencing. Also, due to the genetic basis of these strategies, protein 
knockout cannot be controlled through dosing or reversed easily [21], which is an 
important consideration for pharmacological applications.  
Inhibition by binding via designer binding proteins 
For post-translational targeting, small molecules remain the workhorses in the 
laboratory and the clinic owing to their proven ability to achieve occupancy-based 
inhibition with high precision. However, despite many successes, organic synthesis is still 
a rate-limiting factor in drug discovery projects [22], Indeed, the identification of lead 
candidates often requires lengthy campaigns involving the creation and screening of small-
molecule libraries, with initial hits often lacking the specificity and/or affinity necessary 
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for efficient squelching of protein activity. Another challenge is that of the ~30,000 genes 
in the human genome, only ~10% encode proteins that are considered suitable for 
pharmacological manipulation via classical rule-of-five-compliant small-molecule drugs, 
leaving a large proportion of the proteome ‘undruggable’ [23-25]. 
Engineered antibodies produced from recombinant DNA technology such as single-
chain Fv (scFv) antibody fragments can be used to achieve inhibition-by-binding and are 
especially attractive alternatives when the target lacks a suitable small molecule-binding 
site. Recombinant antibodies have several advantages including exquisite affinity and 
specificity, as well as more straightforward development and potential for proteome-wide 
coverage [26]. However, the use of such proteins for intracellular applications is limited 
due to the reducing environment of the cytoplasm that disfavors the formation of stable 
disulfide bonds, a necessary step in the folding of most immunoglobulin domains [27]. 
This has prompted the development of intracellular antibody fragments (intrabodies) that 
do not depend on disulfide bonds for folding [28-30] and non-antibody scaffolds such as 
the human fibronectin type III domain (FN3) [31, 32] and designed ankyrin repeat proteins 
(DARPins) that natively lack disulfides [33, 34]. Importantly, all of these modalities have 
been developed for antigen binding inside living cells [28, 31, 33]. Unfortunately, a 
drawback of these approaches is that attaining maximal effect requires 1:1 stoichiometry 
between inhibitor and target as well as sustained equilibrium target occupancy. Moreover, 
methods based on induced proteolysis can degrade proteins regardless of their function, a 
feat that is not possible with conventional occupancy-based inhibitors. Such function-
independent knockout can also be achieved with engineered antibodies/antibody mimics; 
however, target binding alone does not always lead to inactivation.  
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Targeted protein degradation techniques 
Proteolysis-targeting chimeric molecules 
Proteome editing technology represents an orthogonal strategy for post-translational 
control of protein function based on the principle of inhibition-by-degradation whereby the 
“inhibitor” hijacks the cellular quality control machinery to selectively degrade target 
proteins. Owing to the catalytic nature of this approach, induced proteolysis overcomes many of 
the drawbacks associated with traditional occupancy-based inhibitors in terms of potency, efficacy, 
duration of action, and target selection. For example, proteome editing can be very efficient 
because both old and new protein molecules are targeted concomitantly, and it can be 
readily reversed. Because proteome editing operates at the post-translational level, it has 
the potential to delineate the functional consequences associated with specific post-
translational modifications by preferentially removing modified proteins while leaving the 
unmodified subpopulations intact. Such distinctions are difficult or impossible to achieve 
with other silencing technologies. 
One of the most advanced strategies for controlling protein levels involves small 
molecules called proteolysis targeting chimeras, or proteolysis-targeting chimeric 
molecules (PROTACs), that bring together an E3 ubiquitin ligase with the target protein to 
promote its degradation [35-37]. PROTACs are heterobifunctional small molecules 
consisting of two specific ligands—one directed to the protein target and one to an E3 
ubiquitin ligase—joined together by a linker. Importantly, since PROTACs are not 
degraded with the protein, they have the ability to reach complete knockdown at sub-
stoichiometric ratios, alleviating the need for sustained target occupancy that limits 
traditional small-molecule inhibitors. 
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The first PROTACs, described in 2001, were generated by linking a 10 amino-acid 
phosphopeptide derived from IκBα, which binds the Skp1-Cullin-F-box (SCF) E3 ubiquitin 
ligase complex of the cullin-RING ubiquitin ligase (CRL) family, to the small molecule 
ovalicin, which covalently binds to the active site of methionine aminopeptidase 2 
(MetAP-2) [38]. In the presence of this chimeric compound, MetAP-2 was recruited to 
SCF, ubiquitinated, and degraded in a PROTACs-dependent manner. Using the same 
phosphopeptide linked to estradiol and dihydroxytestosterone enabled chemical 
knockdown of estradiol receptor (ER) and androgen receptor (AR), respectively [39]. To 
develop conditionally-active degraders, a 10-residue tyrosine kinase substrate sequence 
was linked to a peptide ligand for the von Hippel-Lindau (VHL) protein, a substrate 
receptor of the Cullin2 (CUL2) E3 ligase complex from the CRL superfamily. The 
resulting “phosphoPROTACs” displayed inducible silencing activity that was activated by 
a given receptor tyrosine kinase [40]. Despite these and other early successes, first-
generation, peptide-based designs suffered from multiple limitations, including large size, 
poor cellular permeability and metabolism, thereby limiting their therapeutic viability. 
Efforts to overcome these permeability issues have focused on entirely small-
molecule based designs. The first such example conjugated an imidazoline derivative that 
binds the E3 ubiquitin ligase MDM2 to small molecule ligands of AR [41], which 
addressed the permeability issue but were not very potent. Along similar lines, Hashimoto 
and coworkers created hybrids between methyl bestatin, which binds the E3 ligase called 
inhibitor of apoptosis protein (IAP), and all-trans retinoic acid (ATRA), an endogenous 
ligand of cellular retinoic acid binding proteins CRABP-I and -II. These molecules, named 
SNIPERS (specific and non-genetic IAP-dependent protein erasers), promoted efficient 
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degradation of their protein targets; however, high doses (≥1 µM) were required for 
efficacy and numerous off-target effects were observed due to the lack of specificity of 
bestatin [42]. More recently, Crews and coworkers described a new generation of 
nonpeptidic PROTACs in which the peptide moiety of earlier designs was replaced with a 
high-affinity, small-molecule ligand for the VHL substrate receptor of the CUL2 E3 
complex [43]. When linked to ligands for various targets such as the estrogen-related 
receptor alpha (ERRα) and the serine-threonine kinase RIPK2, efficient target degradation 
was observed with half-maximal effective concentration (EC50) values ranging from <1 to 
100 nM. Similar results were obtained with nonpeptidic PROTACs comprised of 
thalidomide and related molecules that bind with high affinity to the cereblon (CRBN) 
component of CRL complexes [44, 45]. 
Overall, PROTACs have evolved from early peptide-based compounds to more 
drug-like, small-molecule-based designs that enable chemical knockout in cells and in 
mice, and are just now entering the clinic [46]. Nonetheless, enhancements to potency, 
selectivity, delivery, metabolic stability, and bioavailability are still needed. These efforts 
will likely focus on optimizing linker length/composition, expanding the diversity of E3s 
recruited and protein substrates degraded, and developing targeted delivery strategies such 
as antibody-PROTACs conjugates that use the specificity of monoclonal antibodies to 
transport conjugated PROTACs payloads into desired cells and tissues. Such efforts will 
likely benefit from a recent structural study of the ternary complex between the E3 ligase, a 
PROTAC, and its target [47], shedding light on the mechanism and offering new 
opportunities for rationally optimizing PROTACs. Beyond their clinical development, 
PROTACs have also been adapted for preclinical target validation. For example, the dTAG 
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[48] and HaloPROTACs [49] schemes leveraged small-molecule ligands for FKB12 and 
HaloTag to selectively degrade fusion proteins comprised of FKB12 or HaloTag, 
respectively. Due to the wide availability of such fusion proteins in biological studies, the 
dTAG and HaloPROTACs degraders should prove useful as chemical genetic tools. 
Heterobifunctional protein-based degraders 
Although PROTACs represent a promising approach for degrading proteins of 
interest including essential drivers of human disorders, their generation is still limited by a 
lack of available ligands that link an E3 ubiquitin ligase with a desired protein as well as 
by technical difficulties associated with creating such ligands de novo [50]. Protein-based 
chimeras bypass these challenges by leveraging recombinant DNA technology to create 
hybrid proteins comprised of one domain having E3 ubiquitin ligase activity and another 
domain having target-binding activity. The resulting chimeras promote polyubiquitination 
and subsequent proteasomal degradation of their protein substrates when ectopically 
expressed in cells. An advantage of this approach is the potential to effectively bridge 
ubiquitin conjugation to virtually any intracellular target provided that a protein-binding 
domain is available or can be engineered. 
In the earliest examples, target recognition was achieved by leveraging pairwise 
interactions that involve the protein of interest. For example, Zhou and coworkers 
demonstrated efficient protein knockout by genetically fusing the F-box protein β-TrCP 
with a peptide derived from the E7 protein encoded by human papillomavirus type 16 that 
is known to interact with retinoblastoma protein pRB [51, 52]. Following ectopic 
expression, the engineered chimera recruited pRB to the SCF machinery, a multi-protein 
E3 complex from the CRL superfamily, for ubiquitination and destruction. A handful of 
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other studies have similarly exploited natural protein-protein interactions, whereby fusion 
of an interacting partner protein to an E3 (or a component of an E3 ligase complex) yielded 
chimeras that silenced different oncoproteins including c-Myc [53], ErbB [54], HIF-α [55], 
and KRAS [56]. Several of these chimeras were even able to reduce angiogenesis and/or 
inhibit tumor growth following delivery by viral vectors [53, 55, 56], revealing the promise 
of this approach for therapeutic knockout of cancer targets. 
Antibody-like heterobifunctional protein-based degraders 
In a notable departure from these earlier efforts, our group reported a customizable 
proteome editing technology that could be extended beyond naturally occurring binding 
pairs. Specifically, we created heterobifunctional hybrids, called “ubiquibodies” (uAbs), by 
genetically fusing an E3 to an engineered antibody or to non-antibody scaffolds that bind 
specifically to proteins of interest [57, 58]. In the earliest designs, the flexible ubiquitin-
tagging capacity of the human RING/U-box-type E3 ligase CHIP (carboxyl terminus of 
Hsc70-interacting protein) was tethered to different synthetic binding proteins such as a 
single-chain antibody fragment (scFv), a designed ankyrin repeat protein (DARPin), or a 
fibronectin type III (FN3) monobody. The resulting ubiquibodies efficiently redirected 
structurally diverse protein substrates, including β-galactosidase (β-gal) and maltose-
binding protein (MBP) both from E. coli, to the UPP for proteolytic degradation 
independent of their biological function or native interactions [57]. Around the same time, 
Affolter and coworkers developed a similar strategy called “deGradFP” for shunting GFP-
tagged proteins to the proteasome using a chimera between the F-box domain of 
Drosophila melanogaster Slmb that recruits the SCF machinery and a camelid-derived 
VHH nanobody specific for GFP [59]. Likewise, Sapkota and coworkers developed 
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ubiquibodies (under the name AdPROM for affinity-directed protein missile) that also 
degraded GFP-tagged proteins using the same anti-GFP nanobody attached to the VHL 
substrate receptor of the CRL system [60].  
A distinct advantage of ubiquibodies is their highly modular architecture, which 
enables target selection to be rewired by simply swapping the synthetic protein-binding 
domain. For example, targeted proteolysis has been achieved for a diverse array of protein 
substrates including eukaryotic proteins (ASC [61], Lck,[62] and SHP2 [61, 63]), 
intraneuronal bacterial proteins (Clostridium botulinum neurotoxin (BoNT) proteases) 
[64], and fluorescent proteins (FPs) [60, 61, 63, 65, 66]. Moreover, by incorporating 
synthetic binding proteins that recognize particular protein states (e.g., active vs. inactive 
conformation, mutant vs. wild-type, post-translationally modified, etc.), it becomes 
possible to deplete certain protein subpopulations while sparing others [52, 54, 58, 63] 
Also, in contrast to PROTACs where ligands for new substrates are hard to come by, 
Figure 1.2 Ubiquibodies hijack the UPP for targeted protein degradation.  
Schematic representation of ubiquibodies, chimeric fusions comprised of an E3 ubiquitin 
ligase catalytic domain (E3*) and a designer binding proteins (DBP) that hijack the 
mammalian ubiquitin proteasome pathway for degradation of desired protein targets (T). 
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expanding the number of targets for ubiquibodies including those deemed undruggable is 
made relatively straightforward by library-based screening methods such as phage display 
[67], ribosome display [68], or yeast surface display [69]. Similarly, changing the E3 
domain can readily reprogram ubiquitination kinetics or the mechanism of ubiquitin 
transfer. Indeed, a number of different E3 domains have been developed for ubiquibody-
mediated knockdown including stand-alone E3s such as CHIP [57, 63, 66], E3 substrate 
adaptors/receptors that associate with larger E3 ligase complexes [59-63, 65].  
Bacterial and viral E3 ubiquitin ligases 
In the continuous battle between pathogens and their hosts, it is now firmly 
established that many bacteria and viruses counteract immune defense by inhibiting or 
redirecting the ubiquitination machinery of the host. One common immune evasion tactic 
used by these invaders is the deployment of their own E3 ubiquitin ligases that selectively 
target host immunoproteins for proteasomal degradation. By degrading important host 
adaptor and signaling proteins, bacteria and viruses effectively disable multiple innate 
immune pathways including the production of and response to interferons as well as other 
innate host defense mechanisms as discussed below. 
Although some bacterial species contain a prokaryotic ubiquitin-like protein (Pup) 
system for the post-translational modification and degradation of proteins [70], most lack a 
canonical UPP and LP. Nonetheless, the versatility of these systems in regulating protein 
function and cell behavior makes them a particularly attractive target for bacteria. Indeed, 
to dampen the innate immune response during infection, many pathogenic bacteria encode 
effector proteins that either mimic enzymes of the UPP or modulate the activity of these 
host enzymes. Of relevance here are bacterial E3 ligases (or E3 ligase substrate adap
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proteins) that redirect host immunoproteins to the UPP machinery for degradation [71-73]. 
These E3 mimics typically gain access to the host cytosol via direct injection through the 
bacterium’s type III or type IV secretion system [74-76] although some appear to have 
inbuilt protein-transduction domains that facilitate internalization in host cells [77]. 
One of the earliest and most notable examples comes from studies of Shigella 
flexneri, the causative agent of bacillary dysentery. After being phagocytosed by the host, 
S. flexneri bacteria deliver a cocktail of type III effector proteins, mainly consisting of 
OspG, OspI and the 10-member IpaH family, that collectively function to inhibit the 
activation of the NF-κB pathway. The IpaH family members exhibit similarities to 
eukaryotic HECT-type E3s but are classified as novel E3 ligases (NELs) due to the absence 
of sequence and structural homology with any eukaryotic E3s [78, 79]. NELs contain N-
terminal leucine-rich repeat (LRR) regions for substrate recognition and conserved C-
terminal domains (CTDs) with E3 ubiquitin ligase activity. Among these, IpaH9.8, 
IpaH4.5, and IpaH0722 modulate the host inflammatory response by promoting 
proteasome-dependent degradation of NF-κB essential modulator (NEMO), the NF-κB p65 
subunit, and tumor necrosis factor receptor-associated factor 2 (TRAF2), respectively. [72, 
73] Interestingly, OspG and OspI proteins interact with the UPP in the opposite way, by 
preventing protein degradation. Specifically, OspG binds to activated E2s to bypass the 
ubiquitination of IκBα [80], an NF-κB inhibitor, while OspI disrupts the NF-κB pathway 
by preventing the polyubiquitination of UBC13 [81]. 
Viruses have also evolved elegant strategies for exploiting or avoiding the 
ubiquitin-proteasome system [82, 83]. Like their bacterial counterparts, viral genomes 
encode substrate adaptor proteins that recruit host E3 ligases or stand-alone E3 ligases, 
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which induce proteolysis of host immune factors that might have harmful effects on the 
viral life cycle. For example, Kaposi sarcoma herpesvirus (KSHV) encodes a viral E3 
ligase of the RING-CH family named K3 that utilizes the UPP to ubiquitinate major 
histocompatibility complex I (MHC-I), leading to its lysosomal degradation in a ubiquitin-
proteasome-dependent manner [84]. Likewise, the infected cell protein 0 (ICP0) of herpes 
simplex virus type 1 (HSV-1) is a viral E3 that induces UPP-dependent degradation of 
promyelocytic leukemia protein (PML) and Sp100, thereby avoiding antiviral sensing [85]. 
The E6 oncoprotein from human papillomavirus (HPV) is an example of a viral adaptor 
protein that recruits the cellular E3 ubiquitin ligase E6-AP to induce ubiquitination and 
degradation of p53, thereby allowing viral replication [86]. 
Therapeutic delivery challenges 
Finally, engineered degraders must be able to efficiently enter cells if they are to be 
translated into the clinic. Unfortunately, intracellular delivery of protein-based therapeutics 
represents a significant obstacle as most globular protein drugs do not spontaneously cross 
plasma membranes due to their relatively large size and biochemical properties [50]. 
Efforts to overcome the delivery challenge in the context of targeted protein degradation 
have primarily focused on viral delivery methods [53, 55, 56]. In another recent study, 
Hantschel and coworkers used a chimeric bacterial toxin to deliver ubiquibodies in cancer 
cells [62].  
Approximately 30 cell-permeable proteins (CPPs or cell penetrating peptides) , 
which are able to cross cellular membranes, have been identified from natural sequences, 
modified natural sources, or isolated de novo [87]. CPPs have become widely manipulated 
for the delivery of covalently attached and non-covalently associated cargos including 
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nucleic acids, proteins, small molecules, and imaging agents. Recently, it was discovered 
that the LRR motif-containing bacterial effectors YopM from Yersinia enterocolitica [88], 
SspH1 from Salmonella typhimurium [89], and IpaH effectors from Shigella flexneri [90] 
are autonomously translocated into mammalian cells as a direct result of their N-terminal 
2αH protein domains. Furthermore, they showed that the 2αH domain is necessary and 
sufficient for cell-penetration, as genetic fusion to other proteins, like GFP, resulted in 
their cellular uptake as well. 
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CHAPTER 2 - ENGINEERING BACTERIAL E3 UBIQUITIN LIGASES WITH 
BROAD-SPECTRUM SILENCING 
Introduction 
Manipulation of the ubiquitin-proteasome pathway to achieve targeted silencing of 
cellular proteins has emerged as a reliable and customizable strategy for remodeling the 
mammalian proteome. One such approach involves engineering bifunctional proteins called 
ubiquibodies that are comprised of a synthetic binding protein fused to an E3 ubiquitin 
ligase, thus enabling post-translational ubiquitination and degradation of a target protein 
independent of its function. Here, we attempted to broaden the range of E3s that can be 
functionally reprogrammed as bifunctional ubiquibody chimeras. However, in a notable 
departure from previous efforts involving mammalian E3s, we focused instead on a set of 
effector proteins from microbial pathogens that mimic host E3 ubiquitin ligases and hijack 
the UPP machinery to dampen the innate immune response during infection [71, 91]. The 
intrinsic plasticity of these enzymes led us to hypothesize that bacterial E3s could be 
manipulated for targeted proteolysis just like their mammalian counterparts.  
Indeed, robust target silencing was achieved with a ubiquibody comprised of the 
Shigella flexneri E3 ligase IpaH9.8, which exhibits similarities to eukaryotic HECT-type 
E3s but is classified as a novel E3 ligase (NEL) due to the absence of sequence and 
structural homology with any eukaryotic E3s [71, 74, 79, 91, 92]. Specifically, when the C-
terminal catalytic NEL domain of IpaH9.8 was fused to the GFP-specific FN3 monobody 
GS2 that specifically recognizes green fluorescent protein (GFP), was observed to potently 
eliminate GFP and its spectral derivatives as well as 15 different FP-tagged mammalian 
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proteins that varied in size (27–179 kDa) and subcellular localization (cytoplasm, nucleus, 
membrane-associated, and transmembrane). Furthermore, GS2-IpaH9.8 showed equivalent 
activity regardless of its mode of expression or that of its target. Together, these results 
demonstrate that GS2-IpaH9.8 is a flexible, modular, and robust methodology for the 
targeted degradation of GFP-tagged substrates in mammalian cells.  
Results 
Engineered IpaH9.8 potently silences GFP in mammalian cells  
To determine whether E3 ubiquitin ligase mimics from pathogenic bacteria could be 
redesigned for silencing of non-native targets, we focused on a panel of 14 candidate 
enzymes representing the major classes of E3s found in bacteria to date (Appendix A) [71, 
91]. This panel included E3 mimics with folds similar to eukaryotic E3s such as HECT-
type, RING or U-box (RING/U-box)-type, and F-box domains, as well as unconventional 
E3s with folds unlike any other eukaryotic E3s such as NEL, XL-box-containing, and 
SidC. In general, ubiquibodies were engineered by removing the native substrate-binding 
domain from each E3 mimic and replacing it with a synthetic binding protein (Fig. 2.1a), 
akin to our previously designed ubidquibodies based on human CHIP [57]. For example, S. 
flexneri IpaH9.8 consists of an N-terminal domain with eight 20-residue leucine-rich 
repeats (LRRs) that mediate binding and specificity to native substrate proteins such as 
NF-κB essential modulator (NEMO) [93] and guanylate-binding proteins (GBPs) [94], 
while the C-terminal domain adopts a novel E3 ubiquitin ligase architecture [79, 92]. 
Hence, we replaced the N-terminal LRR domain of IpaH9.8 with GS2, an FN3 monobody 
that binds GFP with nanomolar affinity (Kd = 31 nM) [95]. By swapping the natural 
substrate recognition function of these enzymes with the GS2 monobody, synthetic E3 
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ligases were created that we hypothesized would target GFP and promote its proteasomal 
degradation. To test this hypothesis, the different GS2-E3 chimeras were transiently co-
expressed along with enhanced GFP (EGFP) in mammalian cells and fluorescence activity 
was monitored by flow cytometric analysis. By far, the most striking depletion of EGFP 
was achieved with GS2-IpaH9.8, which reduced EGFP fluorescence to near background 
levels (Fig. 2.1b). All of the other ubiquibodies showed relatively weak silencing activity 
under the conditions tested here. GS2-NleG5-1, GS2-SspH1, SidC-GS2, and GS2-SopA 
were the most active among these, reducing EGFP fluorescence by ~20-40% (Fig. 2.1b).  
In light of this robust silencing activity, we decided to focus our attention on the 
GS2-IpaH9.8. In cells expressing this chimera, the elimination of EGFP was efficient, with 
removal of up to 90% of the fluorescence activity (Fig. 2.2a and b) and no detectable 
EGFP protein in cell lysates (Fig. 2.2c). Importantly, silencing activity was completely 
abrogated when the catalytic cysteine of IpaH9.8 [74] was mutated to alanine (GS2-
IpaH9.8C337A) and when the non-cognate FN3 monobody AS15, which is specific for the 
Abl SH2 domain [96], was substituted for GS2 (Fig. 2.2a-c), indicating that target 
degradation was dependent on cooperation of both ubiquibody domains. In the case of 
GS2-IpaH9.8C337A, expression in mammalian cells and EGFP binding activity in vitro were 
unaffected by the alanine substitution (Fig. 2.3), confirming that loss of silencing activity 
was due to catalytic inactivation. It should also be noted that removal of the LRR domain 
was essential for knockdown activity, as direct fusion of GS2 to full-length IpaH9.8 that 
had not been truncated resulted in no measurable silencing activity (data not shown). 
Interestingly, the genome sequences of S. flexneri strains indicate that several IpaH family 
members, namely IpaH1.4, IpaH2.5, IpaH4.5, IpaH7.8 and IpaH9.8, are encoded on the 
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220-kb virulence plasmid pWR100 while seven additional ipaH cognate genes are present 
on the chromosome [71]. To determine whether these family members were as proficient as 
IpaH9.8 at degrading EGFP in the ubiquibody context, we generated chimeras between 
GS2 and the catalytic domains derived from each of the pWR100-encoded IpaH family 
members as well as one chromosomally encoded member, IpaH0722. When expressed 
ectopically in cultured cells, all of the IpaH-based ubiquibodies were capable of efficient 
(~90% or greater) EGFP knockdown in mammalian cells (Fig. 2.2c). This result was not 
entirely surprising in light of the high homology shared by the different catalytic domains. 
Indeed, whereas the different IpaH family members were only ~70% similar to IpaH9.8 
overall, the catalytic domains were much more similar (>99%) with just 1-3 amino acid 
substitutions and, in the case of IpaH1.4 and IpaH4.5, minor C-terminal truncations 
(Appendix A).  
To benchmark the potency of our engineered bacterial ligase, we compared the GFP 
silencing activity catalyzed by GS2-IpaH9.8 with that of other synthetic ligases based on 
eukaryotic E3 machinery that have previously been reconfigured for targeted proteolysis 
[51-54, 56, 59-61, 65, 66]. Specifically, the natural substrate-binding domains for several 
eukaryotic E3 ubiquitin ligases from humans including carboxyl terminus of Hsc70-
interacting protein (CHIP), speckle-type POZ protein (SPOP), β-transducing repeat- 
containing protein (βTrCP), and von Hippel-Lindau protein (VHL), as well as the 
Drosophila melanogaster supernumerary limbs (Slmb) protein were replaced with the GS2 
monobody, resulting in a panel of synthetic ligases analogous to GS2-IpaH9.8. When the 
resulting panel of GFP-specific ubiquibodies was transiently co-expressed with EGFP in 
mammalian cells, all were capable of measurably reducing EGFP levels, but silencing 
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activity for each was relatively inefficient (~25-45%) under the conditions tested here (Fig. 
2.c), reminiscent of previous results with a Slmb-nanobody chimera that was similarly 
ineffective at reducing unfused GFP levels [59]. The weak EGFP knockdown observed 
here for Slmb-GS2 was actually an improvement over previous results obtained with a 
chimera between Slmb and a GFP-specific VHH nanobody, cAbGFP4, that was incapable 
of promoting degradation of unfused GFP [59]. It should be noted, however, that the Slmb-
cAbGFP4 fusion eliminated the fluorescence associated with larger GFP fusion proteins, 
suggesting that the data reported here are not necessarily indicative of ubiquibody 
dysfunction but instead may reflect differences in substrate preference/compatibility or 
extent of ubiquitin decoration. Regardless, none of the engineered chimeras involving 
eukaryotic E3s displayed the potency and robustness of GS2-IpaH9.8, which reproducibly 
degraded 90-95% of cellular fluorescence.  
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Figure 2.1 Engineering bacterial E3 ligase IpaH9.8 as a GFP-specific ubiquibody.  
 (a) Linear representation of IpaH9.8, IpaH9.8dLRR, and GS2-IpaH9.8. Numbers refer to 
amino acid positions from N terminus (N) to C terminus (C). The proteins are aligned 
vertically with the LRR and NEL domains of IpaH9.8. IpaH9.8dLRR is a truncated version of 
IpaH9.8 lacking the LRR domain. (b) Flow cytometric analysis of EGFP fluorescence activity 
in HEK293T cells transfected with plasmid pcDNA3-EGFP alone or co-transfected with 
pcDNA3-EGFP and a plasmid encoding one of the bacterial E3-based ubiquibodies as 
indicated. (c) Same as in (b) but with mammalian E3-based ubiquibodies as indicated. Flow 
cytometry data are representative of biological triplicates (three separately transfected wells) 
of the geometric MFI normalized to MFI measured for HEK283T cells expressing EGFP 
alone Error bars represent standard deviation (SD) of the mean. p values were determined by 
paired sample t-test. 
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Figure 2.2 Catalytic domain of IpaH.8 essential for ubiquibody function.  
(a) Representative fluorescence histograms obtained by flow cytometric analysis of EGFP 
fluorescence activity in HEK293T cells transfected with pcDNA3-EGFP alone or co-transfected with 
pcDNA3-EGFP and a plasmid encoding one of the following: GS2-IpaH9.8C337A, AS15-IpaH9.8, or 
GS2-IpaH9.8. (b) Flow cytometric quantification of EGFP fluorescence activity for cells described in 
(a). (c) Western blot analysis of HEK293T cell lysates transfected as in (a) and (b). Blots were 
probed with antibodies specific for GFP, 6x-His (that detected tag on each ubiquibody), and GAPDH 
as indicated. An equivalent amount of total protein was loaded in each lane as confirmed by 
immunoblotting with anti-GAPDH. Molecular weight (MW) markers are indicated on left. (d) Flow 
cytometric quantification of EGFP fluorescence activity for HEK293T cells co-transfected with 
pcDNA3-EGFP and a plasmid encoding GS2 fused to one of the IpaH9.8 homologs as indicated. 
Flow cytometry data are representative of biological triplicates (three separately transfected wells) of 
the geometric MFI normalized to MFI measured for HEK283T cells expressing EGFP alone. Error 
bars represent standard deviation (SD) of the mean. p values were determined by paired sample t-
test. 
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Figure 2.3 Characterization of GS2-IpaH9.8 binding activity and expression.  
(a) Binding activity of GS2-IpaH9.8 compared to GS2 alone, IpaH9.8 lacking the LRR 
domain (IpaH9.8 LRR), or catalytically inactive GS2-IpaH9.8C337A as indicated. Activity was 
measured by ELISA using GFP as immobilized antigen and 15 mg/mL of each protein applied 
per well. Detection was performed using anti-FLAG antibody conjugated to horseradish 
peroxidase (HRP). The quenched plate was read at 450 nm (Abs450). Data is the average of 
three biological replicates and error bars are the standard deviation (SD) of the mean. (b) 
Confocal microscopy images corresponding to HEK293T cells transfected with plasmid DNA 
encoding EGFP or co-transfected with plasmid DNA encoding EGFP and either pcDNA3-
GS2-IpaH9.8C337A or pcDNA3-GS2-IpaH9.8 as indicated. Non-transfected HEK293T control 
cells are also depicted. Hoescht stain (blue) denotes cell nuclei, EGFP signal (green) denotes 
FP target expression, and α-His signal (red) corresponds to immunolabeling of expressed 
ubiquibody in permeabilized cells. 
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A broad range of substrate proteins is degraded by GS2-IpaH9.8 
To more deeply explore the substrate compatibility issue, we tested the ability of 
GS2-IpaH9.8 to degrade a range of different substrates. A growing number of GFP-derived 
fluorescent proteins (FPs) have been developed and optimized over the years, providing a 
diverse collection of new tools for biological imaging [97, 98]. To determine the extent to 
which different FP targets could be degraded, GS2-IpaH9.8 was transiently co-expressed in 
mammalian cells with monomeric versions of Emerald, Venus and Cerulean, as well as 
enhanced cyan fluorescent protein (ECFP). Approximately 65-85% of the cellular 
fluorescence activity associated with each of the FPs was ablated by GS2-IpaH9.8, whereas 
the structurally unrelated mCherry protein was not targeted by GS2-IpaH9.8, which was 
expected given the specificity of GS2 for the GFP fold (Fig. 2.4). Interestingly, the 
fluorescence activity of superfolder GFP (sfGFP), a rapidly folding and robustly stable 
mutant of EGFP, was unaffected by GS2-IpaH9.8, consistent with recent findings that 
sfGFP is resistant to proteasomal degradation [99].  
Encouraged by the ability of GS2-IpaH9.8 to degrade different FPs, we next 
evaluated the ability of GS2-IpaH9.8 to degrade structurally diverse, FP-tagged substrate 
proteins. GS2-IpaH9.8 proficiently degraded 15 unique target proteins that varied in terms 
of their molecular weight (27-179 kDa) and subcellular localization (i.e., cytoplasm, 
nucleus, membrane-associated, and transmembrane) (Fig. 2.5a and Fig. 2.6). For example, 
GS2-IpaH9.8 triggered degradation of 80-92% of the fluorescence activity associated with 
FP fusions involving the cytoplasmic proteins α-actinin, α-synuclein (α-syn), extracellular 
signal-regulated kinase 2 (ERK2), focal adhesion kinase (FAK), F-tractin, paxillin (PXN), 
and vinculin (VCL) as determined by flow cytometric analysis (Fig. 2.5 and Fig. 2.6). 
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Similarly robust silencing was observed for:  nuclear-targeted FP fusions involving histone 
H2B and the nuclear localization signal (NLS) derived from SV40 Large T-antigen; 
membrane-associated FP fusions involving Harvey rat sarcoma virus oncogene homolog 
carrying the oncogenic G12V mutation (HRasG12V), Src-homology 2 domain-containing 
phosphatase 2 (SHP2), and the farnesyl sequence derived from HRas; and transmembrane 
FP fusions involving epidermal growth factor receptor (EGFR), avian erythroblastic 
leukemia viral oncogene homolog 2 (ErbB2), and mucin 1 (MUC1) (Fig. 2.5a and Fig. 
2.6). Microscopy analysis of representative substrate proteins α-actinin-mEmerald, EGFP-
NLS, farnesyl-mEmerald, and EGFR-mEmerald confirmed the expected subcellular 
localization of each fusion and corroborated the efficient degradation activity measured by 
flow cytometric analysis (Fig. 2.5b). The transmembrane protein EGFR-mEmerald was 
examined by immunolabeling with an antibody specific to the extracellular domain of 
EGFR. Importantly, the α-EGFR signal decreased concomitantly with GFP disappearance 
(Fig. 2.5b), indicating that degradation of the entire transmembrane protein was achieved. 
Taken together, these results establish GS2-IpaH9.8 as a robust proteome editing tool that 
is capable of silencing a broad spectrum of substrates that span several distinct subcellular 
locations. 
GS2-IpaH9.8-mediated proteome editing is flexible and modular  
An attractive feature of ubiquibodies is their highly modular architecture – the E3 
catalytic domain and synthetic binding protein domain can be interchanged to reprogram 
the activity and specificity. Indeed, our results above revealed the ease with which 
different bacterial and eukaryotic E3 domains can be chimerized to form functional 
ubiquibodies. To investigate the interchangeability of the synthetic binding protein domain 
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in IpaH9.8-based ubiquibodies, we first replaced GS2 with other high-affinity GFP-binding 
proteins such as the FN3 monobody GS5 (Kd = 62 nM) [95] or cAbGFP4 (Kd = 0.32 nM) 
[100]. For these constructs, efficient EGFP silencing activity was observed that rivaled that 
seen with the GS2 monobody (Fig. 2.7). Interestingly, introduction of weaker affinity 
(~200-500 nM) FN3 monobodies [95] resulted in less efficient EGFP elimination (Fig. 
2.7), suggesting that silencing activity may be a function of the affinity for the target 
protein. Although, because spatial arrangements and surface complementarity prioritize 
lysine sites for ubiquitination [101], an equally plausible explanation for these findings is 
that the various FN3 domains may differentially orient the ubiquibody with respect to GFP 
in a manner that affects how the substrate is ubiquitinated. 
Figure 2.4 Ubiquibody-mediated silencing of FP variants.  
Flow cytometric quantification of fluorescence activity in HEK293T cells co-transfected with 
plasmids encoding the FP variant and either pcDNA3-GS2-IpaH9.8C337A (white) or pcDNA3-
GS2-IpaH9.8 (grey) as indicated. mCherry served as negative control. Data are biological 
triplicates (three separately transfected wells) of the geometric MFI normalized to MFI 
measured for HEK293T cells expressing the corresponding FP alone. Error bars represent 
standard deviation (SD) of the mean. p values were determined by paired sample t-test. *, p < 
0.01 (compared to HEK293T cells expressing the FP variant only). 
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Figure 2.5 GS2-IpaH9.8 degrades structurally diverse fluorescent protein fusions.  
(a) Flow cytometric quantification of fluorescence activity in HEK293T cells transfected with 
a plasmid encoding the indicated FP fusion alone (dark grey) or co-transfected with the FP 
fusion plasmid and either pcDNA3-GS2-IpaH9.8C337A (white) or pcDNA3-GS2-IpaH9.8 (light 
grey). Data are biological triplicates (three separately transfected wells) of the geometric MFI 
normalized to MFI measured for HEK283T cells expressing the corresponding FP fusion 
protein alone. Error bars represent standard deviation (SD) of the mean. (b) Confocal 
microscopy images corresponding to select FP targets expressed in HEK293T cells 
transfected/co-transfected as described in (a). Hoescht stain (blue) denotes cell nuclei and 
EGFP signal (green) denotes fluorescent proteins. For the EGFR-mEmerald fusion, 
immunostaining with an EGFR-specific antibody (red) is also depicted. p values were 
determined by paired sample t-test. 
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Figure 2.6 Ubiquibody-mediated silencing of additional FP fusion protein targets.  
Flow cytometric quantification of fluorescence activity in HEK293T cells transfected with a 
plasmid encoding the indicated FP fusion alone (dark grey) or cotransfected with the FP 
fusion plasmid and either pcDNA3-GS2-IpaH9.8C337A (white) or pcDNA3-GS2-IpaH9.8 
(light grey). Data are biological triplicates of the geometric MFI normalized to MFI measured 
for HEK283T cells expressing the corresponding FP alone. Error bars represent standard 
deviation (SD) of the mean. *, p < 0.01 (compared to HEK293T cells expressing the FP 
fusion only). 
Figure 2.7 Modularity of ubiquibody platform.  
Flow cytometric quantification of EGFP fluorescence activity in HEK293T cells transfected 
with plasmid DNA encoding EGFP or co-transfected with a plasmid encoding ubiquibody 
chimeras comprised of IpaH9.8 fused to a different GFP-directed binding protein as indicated. 
Data are biological triplicates of the geometric MFI normalized to MFI measured for 
HEK283T cells expressing the corresponding FP alone. Error bars represent standard 
deviation (SD) of the mean. *, p < 0.01 (compared to HEK293T cells expressing EGFP 
variant only). 
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It is worth noting, however, that when each of the bacterial or mammalian E3-based 
ubiquibodies was tested against a different substrate, namely EGFP-HRasG12V, very similar 
results were observed. That is, a handful (e.g., XopL, CHIP, SPOP, and βTrCP) were able 
to reduce EGFP-HRas levels by as much as 60% but none were as effective as IpaH9.8 or 
its homologs, which all degraded ~80-90% of EGFP-HRasG12V (Figure 2.8). 
In all the experiments described above, efficient knockdown was achieved when 
GS2-IpaH9.8 and its corresponding target were transiently expressed. However, transient 
expression is not always an option, due to the experimental timescale, necessity for a 
precise expression profile, or the use of a recalcitrant mammalian cell line. Thus, to 
demonstrate the flexibility of GS2-IpaH9.8-mediated silencing, we evaluated degradation 
activity against target proteins that were expressed as stably integrated transgenes. 
Specifically, when GS2-IpaH9.8 was transiently expressed in cells that stably co-expressed 
EGFP, reduction of fluorescence activity was virtually identical to that observed for 
transiently expressed EGFP (Fig. 2.9a). Robust degradation was also observed for ERK2-
EGFP, H2B-EGFP, and EGFP-HRasG12V, regardless of their mode of expression (Fig 
2.9a). When the ubiquibody and the target were both expressed as stable transgenes, 
thereby eliminating the need for transfection entirely, strong silencing activity was again 
observed for GS2-IpaH9.8 but not its inactive GS2-IpaH9.8C337A counterpart (Fig. 2.9b). 
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Figure 2.8 EGFP-HRasG12V silencing by bacterial- and mammalian-based ubiquibodies.  
(a) Flow cytometric analysis of EGFP fluorescence activity in HEK293T cells transfected 
with plasmid pcDNA3-EGFP-HRasG12V alone or co-transfected with pcDNA3-EGFP-
HRasG12V and a plasmid encoding a ubiquibody comprised of GS2 fused to one of the (a) 
bacterial or (b) mammalian E3 ubiquitin ligases as indicated. Values for geometric mean 
fluorescence intensity (MFI) are shown. (c) Same as in (a) but with plasmid DNA encoding a 
ubiquibody comprised of GS2 fused to one of the IpaH homologs as indicated. Data are 
biological triplicates (three separately transfected wells) of the geometric mean fluorescence 
intensity (MFI) normalized to MFI measured for HEK293T cells expressing EGFP-HRasG12V 
alone. Error bars represent standard deviation (SD) of the mean. p values were determined by 
paired sample t-test. 
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Figure 2.9 Effect of expression modality on GS2-IpaH9.8 efficacy.  
(a) Flow cytometric quantification of EGFP fluorescence activity in HEK293T cells that 
transiently or stably expressed EGFP, ERK2-EGFP, H2B-EGFP, or EGFP-HRasG12V as 
indicated. In all cases, cells were transiently transfected with plasmid DNA encoding either 
pcDNA3-GS2-IpaH9.8C337A (white) or pcDNA3-GS2-IpaH9.8 (grey). (b) Flow cytometric 
quantification of EGFP fluorescence activity in MCF10a cells stably integrated with DNA 
encoding only EGFP-HRasG12V, EGFP- HRasG12V and GS2-IpaH9.8, EGFP- HRasG12V and 
GS2-IpaH9.8C337A, or GS2-IpaH9.8 alone. All data are biological triplicates of the geometric 
MFI normalized to MFI measured for HEK283T cells expressing the EGFP alone. Error bars 
represent standard deviation (SD) of the mean. *, p < 0.01 (compared to HEK293T cells 
expressing the FP fusion only). 
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Discussion 
Ubiquibodies are a relatively new proteome editing modality that enable selective 
removal of otherwise stable proteins in somatic cells [57], with potential applications in 
basic research, drug discovery, and therapy. In this study, we created a new class of 
ubiquibodies that feature bacterial E3 ubiquitin ligases, thereby opening the door to a 
previously untapped source of ubiquitination activity for ubiquibody development. 
Specifically, we evaluated 14 bacterial E3 ligases belonging to a growing class of effector 
proteins that mimic host cell E3 ligases to exploit the ubiquitination pathway [71, 
91]. Most notable among these was IpaH9.8 from S. flexneri, which proved to be a 
remarkable catalyst of protein turnover when directed to target substrates via a genetically 
fused synthetic binding domain. This silencing activity was found to be independent of the 
substrate’s subcellular localization (i.e., cytoplasm, nucleus, plasma membrane) or 
expression modality (i.e., transient versus stable). The only other E3 ligases that functioned 
comparably were homologs of IpaH9.8 found in S. flexneri, either on the pWR100 
virulence plasmid or the chromosome [71]. The N-terminal catalytic NEL domains of these 
enzymes share striking homology (99-100%), which explains their similar performance in 
the ubiquibody context. Accordingly, the next best functioning bacterial E3 ubiquitin ligase 
was S. typhimurium SspH1, which is also a NEL type enzyme with 38% identity to 
IpaH9.8 overall and 42% identity within the NEL domain [90]. It should also be pointed 
out that none of the mammalian E3 ubiquitin ligases were able to degrade EGFP levels 
below 60% under the conditions tested here. While the reasons for this are not entirely 
clear, given the successful knockdown results reported previously for these different E3 
ligases in the ubiquibody format [57, 59-61, 65, 66], it is possible that EGFP may represent 
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a poor substrate for these engineered chimeras. We believe that the inherent 
conformational flexibility required to ubiquitinate these structurally diverse substrates 
helps to explain the NEL motif’s remarkable ability for customizable target degradation. It 
should also be pointed out that while the work here leveraged previously confirmed E3 
ubiquitin ligases, an analogous swapping strategy could be used to create GS2-based 
ubiquibodies for identifying novel E3 ligases. Such an approach could enable systematic 
identification of E3 ligases, which is an important objective given that the human genome 
encodes over 600 putative E3 ligases [102] and bacterial genomes likely encode hundreds 
of others, many of which remain to be validated as catalysts of ubiquitin transfer. 
From a drug development standpoint, pharmacological control of gene products has 
traditionally been achieved using small molecule inhibitors that target enzymes and 
receptors having well-defined hydrophobic pockets where the small molecules are tightly 
bound. Unfortunately, a majority (~80-85%) of the human proteome is comprised of 
intractable targets, such as transcription factors, scaffold proteins, and non‐enzymatic 
proteins, which have yet to be inhibited pharmacologically and thus have been deemed 
'undruggable' [23, 24]. As an alternative, a number of techniques for silencing proteins at 
the DNA or RNA level are now available such as CRISPR, RNAi, TALENs, and ZFNs, 
with the first RNAi therapy, patisiran, gaining approval in 2018 for hereditary transthyretin 
amyloidosis [103]. Nonetheless, new adaptable technologies, such as ubiquibodies and the 
related PROTACs technology, that offer temporal and post-translational control over 
protein silencing are desirable especially because of their potential to overcome some of 
the limitations associated with nucleic acid targeting-based approaches such as 
irreversibility, lack of temporal control, and off-target effects [19, 104-106]. In principle, 
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both ubiquibodies and PROTACs can degrade proteins regardless of their function, 
including the currently undruggable proteome. Moreover, unlike conventional 'occupancy-
based' therapeutics, ubiquibodies and PROTACs act catalytically, making them 
substantially more potent than the target-binding antibody mimetics and small molecule 
inhibitors, respectively, from which they are built. 
Materials and Methods 
Plasmids  
All plasmids used in this study are provided in Appendix C. E. coli strain DH5α 
was used for the construction and propagation of all plasmids. To construct pcDNA3-
EGFP, EGFP was PCR amplified using primers that introduced a 5’ Kozak sequence and 
the resulting PCR product was ligated into pcDNA3. Plasmid pCDH1-ERK2-EGFP was 
created by gene assembly of ERK2 and EGFP using overlap extension PCR with primers 
that introduced a 5’ Kozak sequence followed by ligation into pCDH1. Plasmid pcDNA3-
EGFP-NLS was created by PCR amplification of EGFP with primers that added a 5’ Kozak 
sequence and 3’ SV40 NLS sequence and then ligation of the PCR product into pcDNA3. 
Plasmid pcDNA3-SHP2-EGFP was created by PCR amplification of SHP2 with a 5’ Kozak 
sequence followed by ligation into pcDNA3-EGFP. Plasmid pcDNA3-EGFP-HRasG12V 
was generated by PCR amplification of EGFP-HRasG12V from plasmid mEGFP-HRasG12V 
and the PCR product was subsequently ligated into pCDH1. 
For creation of GFP-directed ubiquibodies, plasmid pcDNA3-HF-GS2 was created 
by PCR amplification of GS2 from pHFT2-GS2 [95] using primers that introduced 
upstream Kozak, 6x-His, and FLAG sequences followed by ligation into pcDNA3 such that 
BamHI and EcoRI restriction sites were available upstream of GS2 for generating N-
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terminal fusions. For C-terminal fusions, plasmid pcDNA3-GS2-FH was created by PCR 
amplifying GS2 with primers that introduced an upstream Kozak sequence and 
downstream NheI and SbfI restriction sites followed by ligation into pcDNA3. The genes 
encoding AvrPtoB, IpaH9.8, NleG2-3, NleG5-1, NleL, SlrP, SopA, SPOP, SspH1, SspH2, 
and XopL were PCR amplified with primers introducing NheI and SbfI sites, after which 
the resulting PCR products were ligated in pcDNA3-GS2-FH. The genes encoding 
LegAU13, LegU1, and SidC were PCR amplified with primers that introduced BamHI and 
EcoRI sites, after which the resulting PCR products were ligated in pcDNA3-HF-GS2. 
Plasmid pcDNA3-GS2-CHIP was created by PCR amplification of GS2 from pHFT2-GS2 
using primers that introduced an upstream HindIII and Kozak sequence and downstream 
NheI site, followed by ligation into pcDNA3-R4-CHIPdTPR in place of scFvR4. Plasmids 
pcDNA3-VHL-GS2 and pcDNA3-βTrCP-GS2 were created by PCR amplification of genes 
encoding VHL and βTrCP with primers that introduced HindII and XhoI (VHL) or BamHI 
and XhoI (βTrCP) sites after which the resulting PCR products were ligated in place of 
NSlmb in pcDNA3-NSlmb-GS2. Plasmids pcDNA3-GS2-IpaH9.8C337A, pcDNA3-GS2-
IpaH0722, pcDNA3-GS2-IpaH1.4, pcDNA3-GS2-IpaH2.5, pcDNA3-GS2-IpaH4.5, and 
pcDNA3-GS2-IpaH7.8 were created by site-directed mutagenesis of pcDNA3-GS2-
IpaH9.8. The following genes were purchased: SspH1 (Twist Biosciences), IpaH9.8 (Twist 
Biosciences), VHL (GenScript, Ohu23297D), LubX (Twist Biosciences), LegU1(IDT), and 
LegAU13 (IDT). All others were amplified from existing plasmids in our laboratory stocks 
or from genomic DNA. 
Plasmid pET24d-GS2-IpaH9.8 and pET24d-IpaH9.8dLRR were created by PCR 
amplification of full-length GS2-IpaH9.8 and truncated IpaH9.8dLRR, respectively, with 
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primers that introduced NcoI and NotI (GS2-IpaH9.8) or NheI and NotI (IpaH9.8dLRR ) 
sites, after which the resulting PCR products were ligated into pET24d(+). Plasmid 
pET28a-GS2 was created by PCR amplification of GS2 from pHFT2-GS2 using primers 
that introduced an upstream NcoI site and downstream FLAG, 6x-His, and HindIII 
sequences, after which the resulting PCR product was ligated into pET28a(+). Plasmid 
pTriEx-3-GS2-IpaH9.8C337A was created by PCR amplification of GS2-IpaH9.8C337A from 
pcDNA3-GS2-IpaH9.8C337A with primers that introduced EcoRV and HindIII sites, after 
which the resulting PCR product was ligated into pTriEx-3. Plasmid pET28a-EGFP was 
created by PCR amplification of GFP with primers adding C-terminal 6x-His tag, after 
which the resulting PCR product was ligated in pET28a(+). All plasmids were verified by 
DNA sequencing at the Cornell Biotechnology Resource Center (BRC). 
Cell Lines, Culture and Transfection  
All cell lines used in this study are provided in Appendix C. Briefly, HEK293T and 
HeLa cells were obtained from ATCC, HeLa H2B-EGFP cells were kindly provided by 
Elena Nigg, and MCF10A rtTA cells were kindly provided by Matthew Paszek, HEK293T, 
HeLa, and HeLa H2B-EGFP cells were cultured in DMEM with 4.5 g/L glucose and L-
glutamine (VWR) supplemented with 10% FetalCloneI (VWR) and 1% penicillin-
streptomycin-amphotericin B (ThermoFisher) MCF-10a cells were grown in DMEM/F12 
media (ThermoFisher) supplemented with 5% horse serum (ThermoFisher), 20 ng/mL EGF 
(Peprotech), 0.5 mg/mL hydrocortisone (Sigma), 100 ng/mL cholera toxin (Sigma), 10 
µg/mL insulin (Sigma), and 1% penicillin-streptomycin-amphotericin B (ThermoFisher). 
All cells were maintained at 37°C, 5% CO2 and and 90% relative humidity (RH). 
Stable MCF10A rtTA cell lines were generated using Nucleofection Kit V (Lonza) 
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and HyPBase, an expression plasmid for the hyperactive version of the PiggyBac 
transposase. Transposition of MCF10A rtTA cells was performed to generate the following 
stable lines:  MCF10A EGFP-HRasG12V; MCF10A EGFP-HRasG12V:GS2-IpaH9.8; 
MCF10A EGFP- HRasG12V:GS2-IpaH9.8C337A; and MCF10A GS2-IpaH9.8. Stable cell 
lines were selected using 200 µg/mL hygromycin B (ThermoFisher).   
Stable HEK293T cell lines expressing EGFP, EGFP-HRasG12V, ERK2-EGFP, 
d2EGFP were generated by lentiviral transformation. Specifically, pLV-IRES-eGFP, 
pcDH1-EGFP-HRasG12V, pcDH1-ERK2-EGFP, or pHIV-d2EGFP were transfected into 
HEK293T cells along with psPAX2 and pMD2.G by calcium phosphate transfection. 
Media was replaced after ~16 h, followed by a 48-h incubation to allow virus production. 
Viral supernatant was removed and Polybrene (Sigma-Aldrich) added to a final 
concentration of 8 µg/mL, followed by clearance of cell debris by centrifugation at 2,000 
rpm for 5 min. Resultant supernatant was diluted 1:6 with cell media and added to 
previously plated HEK293T cells for stable integration. HEK293T-EGFP and HEK293T 
ERK2-EGFP cell lines were selected by fluorescence activated cell sorting (BD 
FACSAria). The HEK293T-EGFP-HRasG12V cell line was selected using 1 µg/mL 
puromycin (Sigma-Aldrich).  
Western blot analysis 
HEK293T cells were plated at 10,000 cells/cm2 and transfected as describedabove 
before lysis with RIPA lysis buffer (Thermo Fisher). Lysates were separated on Any kD 
polyacrylamide gel (Bio-Rad) and transferred to PVDF membranes. α-HIS-HRP (Abcam), 
α-GFP (Krackeler) and α-GAPDH (Millipore) antibodies were diluted 1:5,000 and in 
TBST + 1% milk and incubated for 1 h at room temperature. Secondary antibody goat anti-
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mouse IgG with HRP conjugation (Promega) was diluted at 1:2,500 and used as needed. 
Microscopy  
Cells were plated at 10,000 cells/cm2 on a glass bottom 12-well plate pre-treated 
with poly-L-lysine (Sigma-Aldrich). After seeding for 16-24 h, cells were transfected with 
1 µg total DNA at a 1:2 ratio of DNA:jetPrime (Polyplus Transfection). cells were 
transfected with 0.05 µg of target, 0.25 µg of ubiquibody or control, and balanced with 
empty pcDNA3 vector. Culture media was replaced 4-6 h post-transfection. Then, 24 h 
post-transfection, cells were fixed with 4% paraformaldehyde. For EGFR-EGFP samples, 
cells were blocked with 5% normal goat serum in PBS for 2 h at room temperature. The 
anti-EGFR antibody (Cell Signalling #4267) was diluted 1:200 in 5% normal goat serum in 
PBS and incubated overnight at 4°C. Cells were washed three times with PBS, then 
incubated for 1 h at room temperature with anti-rabbit-AF647 diluted 1:200 in 5% normal 
goat serum in PBS. Cells were washed three times with PBS. Cell nuclei were stained with 
Hoescht diluted 1:10,000 in PBS for 10 min, then washed three times in PBS. Samples 
were imaged on a inverted Zeiss LSM88-confocal/multiphoton microscope (i880) using a 
40x water immersion objective. Images were analyzed with FIJI.  
Flow cytometric analysis  
Cells were passed into 12-well plates at 10,000 cells/cm2. 16-24 h after seeding, 
cells were transiently transfected with 1 µg total DNA at a 1:2 ratio of DNA:jetPrime 
(Polyplus Transfection). Cells were transfected with 0.05 µg of target, 0.25 µg of 
ubiquibody or control, and balanced with empty pcDNA3 vector. Culture media was 
replaced 4-6 h post-transfection. Then, 24 h post-transfection, cells were harvested and 
resuspended in phosphate buffered saline (PBS) for analysis using a BD FACSCalibur or 
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BD FACSAria Fusion. FlowJo Version 10 was used to analyze samples by geometric mean 
fluorescence determined from 10,000 events.  
Protein expression and purification  
Purified proteins were obtained by growing E. coli BL21(DE3) cells containing a 
pET28a-based plasmid encoding the desired protein or Rosetta(DE3) cells containing a 
pTriEx-3-based plasmid in 200 mL of Luria-Bertani (LB) medium at 37°C. Expression was 
induced with 0.1 mM IPTG when the culture density (Abs600) reached 0.6-0.8 and growth 
continued for 6 h at 30°C. Cultures were harvested by centrifugation at 4,000xg for 30 min 
at 4°C. Cell pellets were stored at -20°C overnight. Thawed pellets were resuspended in 10 
mL equilibration buffer (25 mM Tris-HCl, pH 7.4, 500 mM NaCl and 20 mM imidazole) 
and lysed with a high-pressure homogenizer (Avestin Emulsi-Flex C5). The insoluble 
fraction was cleared by centrifugation at 12,000xg for 30 min at 4°C. His-tagged protein 
was purified by gravity flow using 500 µL HisPur Ni-NTA resin (ThermoFisher). The 
soluble fraction was passed through the resin, after which the resin was washed with 3 mL 
of wash buffer (25 mM Tris-HCl, pH 7.4, 500 mM NaCl and 50 mM imidazole). Protein 
was eluted with 1.5 mL elution buffer (25 mM Tris-HCl, pH 7.4, 500 mM NaCl and 250 
mM imidazole). Purified fractions were desalted and concentrated (Pierce PES Protein 
Concentrators).  
ELISA  
A 96-well enzyme immunoassay plate was coated with 100 µL of EGFP at 10 
µg/mL in 0.05 M NaCO3 buffer, pH 9.6 at 4°C overnight. The plate was then washed three 
times 200 µL PBST (1x PBS + 0.1% Tween 20) per well and blocked with 250 µL PBS 
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with 3% milk per well at room temperature for 3 h, slowly mixing. The plate was washed 
three more times, followed by the addition of serial dilutions of purified proteins in 
blocking buffer at 60 µL per well. Plate was incubated at room temperature, slowly mixing 
for 1 h. The plate was washed three times to remove un-bound protein and then incubated 
with 50 µL/well of anti-FLAG (DDDYK) antibody conjugated to horseradish peroxidase 
(HRP) diluted 1:10,000 in PBST + 1% milk for 1 h with slow mixing. The plate was 
washed three times before the addition of 50 µL/well 1-Step Ultra TMB (3,3',5,5'-
tetramethylbenzidine) (ThermoFisher). The reaction was incubated with slow mixing and 
then quenched with 50 µL/well of 3N H2SO4 and read at 450 nm.  
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CHAPTER 3 – EXPANDING UBIQUIBODY TARGETING WITH ENGINEERED 
DESIGNER BINDING PROTEINS 
Introduction  
Previously, we demonstrated the highly modular architecture of ubiquibodies – 
interchanging both the E3 catalytic domain and designer binding domain identified the 
ubiquibody GS2-IpaH9.8 that potently eliminated a broad-spectrum of GFP tagged 
proteins. To explore the therapeutic potential of our ubiquibodies, we wanted to expand 
the specificity of IpaH9.8 ubiquibodies beyond GFP. While there have been extensive 
numbers of binding domains isolated against disease-related proteins, many of these 
recognize extracellular protein epitopes which are not compatible with our ubiquibodies 
which require access to the intracellular ubiquitin proteasome pathway [107-111]. We 
were able to evaluate several well-characterized binding domains as ubiquibody fusions 
against the intracellular disease-relevant proteins SHP2, Ras, and ERK2. 
When IpaH9.8 was paired with the SHP2-specific FN3 NSa5, efficient silencing 
of SHP2-EGFP was achieved that was comparable to that observed from the GFP-
specific ubiquibody GS2-IpaH9.8.  IpaH9.8 was also successfully reprogrammed to 
degrade EGFP-KRas when fused to the KRas-specific FN3s RasInI and RasInII as well 
as the KRas-specific sso7d R11.1.6. Furthermore, all three Ras-specific ubiquibodies – 
RasInI-IpaH9.8, RasInII-IpaH9.8, and R11.1.6-IpaH9.8 – showed preference for the 
cancer-prevalent isoforms KRasG12C, KRasG12D, and KRasG12V over wild-type KRas.  
Interestingly, minimal elimination of ERK2-EGFP was observed when IpaH9.8 
was paired with a panel of ERK2-specific DARPins. We hypothesized that the DARPin 
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scaffold might not be the ideal fusion partner for IpaH9.8, so we utilized yeast surface 
display to isolate ERK2-specific members from a naïve FN3 library. Twenty clones 
were then analyzed for their ability to degrade ERK2 in mammalian cells when fused to 
IpaH9.8. Interestingly, despite not exhibiting the strongest binding activity, clones 
aERK2-10 and aERK2-16 were the most potent ubiquibodies, depleting ERK2-eGFP to 
~50%, a significant improvement over DARPin-based ERK2-specific ubiquibodies. 
Together, these results further emphasize the modularity of our ubiquibody design and 
the flexibility of IpaH9.8 to accommodate a range of binding domain scaffolds and 
protein targets.  .  
Results 
Targeting disease relevant proteins with IpaH9.8-based ubiquibodies 
To redirect IpaH9.8 activity towards disease-relevant proteins, we first 
investigated the compatibility of the IpaH9.8 catalytic domain with three different FN3s 
– NSa1, NSa5, and CS3  – which are specific for the Src-homology 2 (SH2) domain of 
SHP2 [112].  The resulting NSa1-IpaH9.8, NSa5-IpaH9.8, and CS3-IpaH9.8 chimeras 
were tested for their ability to silence SHP2-EGFP by flow cytometric analysis. NSa1-
IpaH9.8 elicited no significant degradation and CS3-IpaH9.8 resulted in moderate, but 
highly variable depletion of SHP2-EGFP. However, NSa5-IpaH9.8 exhibited strong 
silencing activity, degrading SHP2-EGFP as efficiently as the GFP-specific GS2-
IpaH9.8 ubiquibody (Fig. 3.1).  
Next, we evaluated how IpaH9.8 performed when paired with Ras-specific FN3s 
RasInI and RasinII [113], as well as the Ras-specific sso7d R11.1.6 [114]. These three 
Ras-specific ubiquibodies – RasInI-IpaH9.8, RasInII-IpaH9.8, and R11.1.6-IpaH9.8 – 
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were tested for their ability to silence EGFP fusions of KRas, KRasG12C, KRasG12D, and 
KRasG12V. R11.1.6-IpaH9.8 facilitated the most robust depletion of all four KRas 
isoforms, displaying preference for the G12C and G12D isoforms (Fig. 3.2). This 
preference was expected, as R11.1.6 was specifically selected to exhibit selectivity for 
G12D vs WT KRas specificity [114]. The extent of degradation did not strictly correlate 
to affinity, however, as KRasG12V depletion matched that of KRasWT, despite R11.1.6’s 
reported higher affinity for that isoform (KRasWT = 41 nM, KRasG12C = 21 nM, 
KRasG12D = 4 nM, KRasG12V = 12 nM [114]). RasInI-IpaH9.8 and RasInII-IpaH9.8, 
while not as potent, also demonstrated preference for the KRasG12C, G12D, and G12V mutant 
isoforms over KRasWT, in line with their previously characterized specificities [113]. 
Together, these results demonstrate the powerful modularity of the ubiquibody design – 
simply swapping the GFP-specific GS2 binding domain with the protein binders NSa5 
and R11.1.6 enabled potent depletion of their respective disease-relevant targets - SHP2 
and KRas, respectively.  
Figure 3.1 IpaH9.8 ubiquibodies against SHP2.  
Flow cytometric quantification of EGFP fluorescence activity in HEK293T cells transfected 
with pcDNA3-SHP2-EGFP alone or cotransfected with pcDNA3-SHP2-EGFP and a plasmid 
encoding the indicated ubiquibody. Data are biological triplicates (three separately transfected 
wells) of the geometric MFI normalized to MFI measured for HEK293T cells expressing 
SHP2-EGFP alone. Error bars represent standard deviation (SD) of the mean. *, p < 0.01 
(compared to HEK293T cells expressing SHP2-EGFP only). 
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Isolation of novel ERK2-specific FN3s for improved ubiquibody targeting 
We have previously characterized a panel of ERK2 targeting ubiquibodies, 
which fused pERK/ERK2-specific DARPins with the catalytic domain of the 
mammalian E3 ubiquitin ligase CHIP [115].  When these ubiquibodies were evaluated 
for their ability to degrade the fluorescent protein fusion ERK2-EGFP in mammalian 
cells, moderate degradation activity (~60-80% ERK2-EGFP remaining) was indeed 
observed, however co-expression of our GFP-targeting ubiquibody GS2-IpaH9.8 
resulted in substantially higher depletion (~25% ERK2-EGFP remaining) (Fig. 3.3).  
Knowing that GS2-IpaH9.8 more potently depleted EGFP than GS2-CHIP (Fig. 2.1c), 
Figure 3.2 IpaH9.8 ubiquibodies against KRAS mutants.  
Flow cytometric quantification of EGFP fluorescence activity in HEK293T cells transfected 
with pcDNA3-EGFP-KRas, pcDNA3-EGFP-KRasG12C, pcDNA3-EGFP-KRasG12D, or 
pcDNA3-EGFP-KRasG12V alone or cotransfected with a plasmid encoding the indicated 
ubiquibody. Data are biological triplicates (three separately transfected wells) of the 
geometric MFI normalized to MFI measured for HEK293T cells expressing the indicated 
KRas protein alone. Error bars represent standard deviation (SD) of the mean. *, p < 0.01 
(compared to HEK293T cells expressing the FP fusion only). 
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we hypothesized that pairing the ERK2-specific DARPins with IpaH9.8 would improve 
our degradation efficiency of ERK2-EGFP. However, this was not true – in fact, only 
EpE89-IpaH9.8 showed moderate improvement over its CHIP counterpart (Fig. 3.3). 
Consequently, these results led us to believe that minimally, IpaH9.8 does not 
pair well with the DARPin scaffold, but potentially ERK2 cannot be targeted with our 
current ubiquibodies. Combining our knowledge that IpaH9.8 exhibited potent activity 
against a variety of targets (EGFP, SHP2, and Ras) when fused to FN3 domains and our 
continued interest in evaluating the role of affinity and binding epitope on ubiquibody 
efficacy, we sought to harness the power of yeast surface display to isolate ERK2-
specific FN3s that we could evaluate for ubiquibody activity. 
Figure 3.3 ERK2 degradation by DARPin-based ubiquibodies.  
Flow cytometric quantification of EGFP fluorescence activity in HEK293T cells transfected 
with pcDNA3 ERK2-EGFP alone or cotransfected with pcDNA3-ERK2-EGFP and a plasmid 
encoding the indicated ubiquibody (e.g for GS2-X, black bar indicates GS2-CHIP and grey 
bar indicates GS2-IpaH9.8). Data are geometric MFI normalized to geometric MFI measured 
for HEK293T cells expressing ERK2-EGFP alone.  
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A naïve FN3 library [116] was screened twice using biotinylated ERK2 
preloaded on Streptavidin magnetic beads, sorting by FACS of full-length clones, and 
then sorted by FACS for members exhibiting binding of ERK2 at 500 nM. The resultant 
population was then diversified by both gene and loop mutagenesis [116], followed by 
two additional rounds of isolation by FACS selections at 300 nM and 100 nM ERK2 
(Fig. 3.4).  Twenty clones were randomly selected for characterization. Sequencing 
analysis revealed that fifteen clones were unique – clones 8, 9, and 14 were unable to be 
sequenced and clones 1 and 4 were identical, as well as clones 2, 15, and 17. Those 
thirteen clones were then analyzed as individual cultures to confirm full-length 
expression and evaluate binding of ERK2 at 50 nM. Of the thirteen remaining clones, all 
the clones, with the exception of aERK2-5 showed binding above control (Fig. 3.5).   
These hits were then cloned as IpaH9.8 fusions and evaluated for their ability to 
deplete ERK2-EGFP in mammalian cells.  The ERK2-specific ubiquibodies elicited the 
reduction of ERK2-as determined by flow cytometry (Fig. 3.6). Specifically, aERK2-
10-IpaH9.8 and aERK2-16-IpaH9.8 depleted ERK2-EGFP to ~50%, which was a 
substantial improvement over DARPin-based ubiquibodies. Analysis of the sequences 
revealed a high occurrence of the BC Loop sequence “YDPDGSD” and DE Loop 
sequence “FYHS”. Interestingly, however, the two best clones as determined by ERK2-
EGFP degradation, aERK2-10 and aERK2-16, had no similarity in their sequences.  
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Figure 3.4 KD measurement of ERK2-specific FN3 FACS libraries.  
Flow cytometric quantification of ERK2 binding by sorted FN3 libraries. 5x106 
cells were incubated with biotinylated ERK2, followed by streptavidin-AF488. 
KD was determined by fitting experimental data points by least squares 
regression.  
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Figure 3.5 Characterization of ERK2-specific FN3 clones. 
(a) Flow cytometric quantification of percentage of yeast cells expressing full-length FN3 
clones on yeast surface as detected by α-cmyc antibody. (b) Flow cytometric quantification of 
ERK2 binding at 50 nM by individual FN3 clones displayed on yeast surface. Data are 
duplicates of geometric MFI normalized to MFI measured for binding observed by each clone 
at 0 nM ERK2. Error bars represent standard deviation (SD) of the mean. Horizontal dashed 
line indicates minimum threshold for positive binding signal.  
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Figure 3.6 ERK2-EGFP degradation by ERK2-specific FN3 ubiquibodies.  
Flow cytometric quantification of EGFP fluorescence activity in HEK293T cells transfected 
with pcDNA3-ERK2-EGFP alone or cotransfected with pcDNA3-ERK2-EGFP and a plasmid 
encoding the indicated ubiquibody (e.g. aERK2-10-IpaH9.8). Data are geometric MFI 
normalized to geometric MFI measured for HEK293T cells expressing ERK2-EGFP alone.  
Figure 3.7 Protein sequence alignments of loop regions from isolated ERK2-specific 
FN3s.  
Fifteen unique clones are ordered according to their potency as ubiquibodies. Loop sequences 
that appear in multiple hits are highlighted.  
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Discussion 
One of the advantages of the ubiquibody design is its modular architecture. 
Previously we demonstrated that choice of E3 ubiquitin ligase domain can dramatically 
affect catalytic activity. Here we further explored ubiquibody modularity – 
demonstrating the ease of reprogramming ubiquibodies to degrade disease-relevant 
targets such as SHP2, Ras, and ERK2, simply by swapping the synthetic designer 
binding protein.  Furthermore, ubiquibodies retain the specificity of their designer 
binding protein, as in the case of R11.1.6-IpaH9.8 substrate preference for KRasG12C 
over KRasWT. This high level of substrate discrimination is vital as we consider the use 
of ubiquibodies as therapeutic agents, as many diseases are driven by proteins with 
small amino acid mutations, as with KRasG12C and KRasWT, or by post-translationally 
modified proteins.  
Importantly, the ability to deplete these clinically important targets along with all 
of the other FP fusions (Chapter 3) serves to highlight the extraordinary modularity of 
the ubiquibody technology. Simply swapping the native substrate-binding domain of the 
E3 ubiquitin ligase can generate a made-to-order ubiquibody with specificity for a 
different substrate protein. Interestingly, Shigella have evolved a similar strategy for 
subverting host defenses during infection whereby plasmid and chromosomally-encoded 
IpaH proteins play a key role in dampening the host inflammatory response by 
mediating proteasomal degradation of NF-κB-related proteins [93, 117]. Specifically, by 
employing different LRR domains, which only share ~50% similarity [90], Shigella are 
able to redirect virtually identical catalytic NEL domains to an array of host proteins 
(e.g., NEMO, U2AF53 for IpaH9.8; Glomulin for IpaH7.8; p65 for IpaH4.5; HOIP for 
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IpaH2.5 and IpaH1.4; TRAF2 for IpaH0722) [71, 91, 117]. 
However, not all synthetic binding domains showed efficacy as ubiquibody 
fusions. While binding affinity is an obvious parameter to attribute these differences to, 
our limited data did not seem to support that hypothesis. Rather, we believe that while 
affinity plays a significant role in ubiquibody efficacy, other factors including the 
choice of binding domain scaffold and proximity of the target binding epitope to surface 
exposed lysines might be more predictive. For these reasons, we sought to isolate our 
own panel of ERK2-specific FN3 binders to test these hypotheses.  
We did identify ERK2-specific binders that, when expressed as IpaH9.8 
ubiquibody fusions, resulted in substantial depletion of ERK2-EGFP in mammalian 
cells. Interestingly, the clones that displayed the highest degradation activity as 
ubiquibodies, aERK2-10 and aERK2-16, did not demonstrate the highest binding 
activity as binding domains. This added more data to support our hypothesis that 
binding affinity is not the only parameter that defines ubiquibody potency.  While 
further characterization of the isolated aERK2 FN3 clones is needed, particularly KD 
calculation, these results underscore the importance for continued investigation into the 
binding domain requirements on efficient ubiquibody-mediated degradation.   
Materials and Methods 
Plasmids and strains 
All plasmids used in this study are provided in Appendix C. E. coli strain DH5α 
was used for the construction and propagation of all plasmids. pcDNA3-GS2-IpaH9.8, 
pcDNA3-SHP2-EGFP, pCDH1-ERK2-EGFP was described previously (Chapter 2). To 
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construct pcDNA3-EGFP-KRas, a synthetic double-stranded gblock (IDT) encoding 
XhoI-KRas-NotI was ligated into pcDNA3-EGFP-HRas digested with XhoI and NotI. 
pcDNA3-EGFP-KRasG12C, pcDNA3-EGFP-KRasG12D, and pcDNA3-EGFP-KRasG12V 
were created through site-directed mutagenesis of pcDNA3-EGFP-KRas.  
pcDNA3-NSa1-IpaH9.8, pcDNA3-NSa5-IpaH9.8, and pcDNA3-CS3-IpaH9.8 
were created by PCR amplification of NSa1, NSa5, and CS3 from pHFT2-SHP2-NSa1, 
pHFT2-SHP2-NSa5, and pHFT2-SHP2-CS3, respectively, with primers that introduced 
an N-terminal HindIII site and Kozak sequence and C-terminal NheI site, followed by 
ligation into pcDNA3-GS2-IpaH9.8 in place of GS2. Similarly, pcDNA3-NSa5-
IpaH9.8C337A was ligated into pcDNA3-GS2- IpaH9.8C337A in place of GS2. pcDNA3-
RasInI-IpaH9.8 and pcDNA3-RasInII-IpaH9.8 were created by PCR amplification of 
RasInI and RasInII from pET24a(+)-RasInI and pET24a(+)-RasInII, respectively, with 
primers that introduced an N-terminal HindIII site and Kozak sequence and C-terminal 
NheI site, followed by ligation into pcDNA3-GS2-IpaH9.8 in place of GS2. pcDNA3-
R11.1.6-IpaH9.8 was created by PCR amplification of R11.1.6 from pE-Sumo-R11.1.6 
with primers that introduced an N-terminal HindIII site and Kozak sequence and C-
terminal NheI site, followed by ligation into pcDNA3-GS2-IpaH9.8 in place of GS2. 
pcDNA3-E40-CHIP, pcDNA3-pE59-CHIP, pcDNA3-EpE82-CHIP, and 
pcDNA3-EpE89-CHIP were created as described previously [115]. pcDNA3-E40-
IpaH9.8, pcDNA3-pE59-IpaH9.8, pcDNA3-EpE82-IpaH9.8, and pcDNA3-EpE89-
IpaH9.8 were created by PCR amplification of E40, pE59, EpE82, and EpE89 with 
primers that introduced an N-terminal HindIII site and Kozak sequence and C-terminal 
NheI site, followed by ligation into pcDNA3-GS2-IpaH9.8 in place of GS2. All 
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plasmids were verified by DNA sequencing at the Cornell Biotechnology Resource 
Center (BRC). 
Strain BL21(DE3) was used for cytoplasmic expression of ERK2 from 
pLK1_ERK2, which introduced an N-terminal Avi tags for biotinylation in vivo using 
pSPI02B-BirA-His and a C-terminal 6x-His tag for affinity purification and 
immunodetection. The Avi tags were used for avidin resin purification, after which 6 × -
His tags were used for Ni-column purification to remove unbound biotin and enhance 
purity. Cultures were grown in LB medium supplemented with 50 µg/ml Ampicillin and 
50 µg/ml Streptomycin and when OD600 reached ~0.3, IPTG (0.4 mM) and biotin (5 
µM) were added for protein induction and biotinylation, respectively. 
Flow cytometric analysis 
HEK293T cells were maintained as described previously (Chapter 2). Cells were 
passed into 12-well plates at 10,000 cells/cm2. 16-24 h after seeding, cells were 
transiently transfected with 1 µg total DNA at a 1:2 ratio of DNA:jetPrime (Polyplus 
Transfection). Cells were transfected with 0.05 µg of target, 0.25 µg of ubiquibody or 
control, and balanced with empty pcDNA3 vector. Culture media was replaced 4-6 h 
post-transfection. Then, 24 h post-transfection, cells were harvested and resuspended in 
phosphate buffered saline (PBS) for analysis using a BD FACSCalibur or BD 
FACSAria Fusion. FlowJo Version 10 was used to analyze samples by geometric mean 
fluorescence determined from 10,000 events.   
Yeast media and plates 
SD-CAA minimal media was prepared containing 20g/L D-glucose, 6.7 g/L 
yeast nitrogen base, 5 g/L casamino acids, 5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4(H2O) at 
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pH 6.0. SG-CAA minimal induction media was prepared containing 18 g/L galactose, 2 
g/L D-glucose, 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 5.4 g/L Na2HPO4, 8.6 
g/L NaH2PO4(H2O) at pH 6.0. YPD media was prepared containing 20g/L dextrose, 
20g/L peptone, 10 g/L yeast extract. SD-CAA plates were prepared containing 20g/L D-
glucose, 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 5.4 g/L Na2HPO4, 8.6 g/L 
NaH2PO4(H2O) and 182 g/L sorbitol. YPD plates were prepared containing 20g/L 
dextrose, 20g/L peptone, 10 g/L yeast extract, 16 g/L agar. Liquid medias were sterile 
filtered. For yeast plates, Na2HPO4, NaH2PO4(H2O), and agar were autoclaved in 0.9X 
final volume and once cooled to room temperature, the remaining components in 0.1X 
final volume were sterile filtered into the autoclaved mixture.  
Yeast library screening with magnetic beads 
Protocols detailed here were based on those detailed in Chen et al., 2013. A 
frozen aliquot containing 10X diversity (1X diversity = 2.5 x 108) of the G4 library 
(EBY100 cells containing the pCT-CON-FN3 library members) was thawed into 1L of 
SD-CAA minimal media. The culture was grown at 30°C at 250 rpm overnight. The 
next day, stocks of the library were prepared by storing 10X diversity in 15% glycerol 
in SD-CAA in -80 C. 30X diversity was then pelleted at 2500xg for 5 min and 
resuspended in 1L of SG-CAA to induce expression. The induced library was incubated 
at 20°C for 24 hours. 
 Initial library screening was performed with Dynabeads MyOne 
Streptavadin T1 to allow for the isolation of weak affinity FN3 binders through avidity 
interaction. Two batches of beads were prepared by incubating 33pmoles of biotinylated 
ERK2 (bERK2) with 10 µL of Dynabeads in 100 µL of PBSA (1X phosphate-buffered 
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saline, 0.1% bovine serum albumin) in 2 mL microcentrifuge tubes. Tubes were 
incubated at 4°C for at least an hour rotating. Immediately before adding cells, the beads 
were incubated on magnet for 5 minutes, supernatant removed, and washed once on 
magnet with 1 mL of PBSA to remove any free antigen.  
 The induced naïve G4 library was measured at OD600 to determine cell density. 
Assuming OD600nm=1 is ~107 cells/mL, 15X library diversity was pelleted at 3000xg for 
5 min and washed with 1 mL of PBSA, then split into two aliquots in 2 mL 
microcentrifuge tubes. Cells were pelleted at 12,000xg for 1 min and resuspended in 1 
mL PBSA. A negative sort was performed by adding 10 µL of bare Dynabeads to each 
tube and incubating at 4°C for at least two hours rotating. Cell and bead mixtures were 
placed on the magnet and unbound cells were immediately transferred to the tubes with 
the washed, ERK2-coated Dynabeads. This positive sort was incubated at 4°C for at 
least two hours rotating. The negative sort beads were washed with 1 mL PBSA on 
magnet, supernatant removed, and remaining beads and cells resuspended in 5 mL of 
fresh SD-CAA. Similarly, the positive sort was washed with 1 mL PBSA on magnet, 
supernatant removed, and beads and cells resuspended in 5 mL of fresh SD-CAA. After 
both positive and negative sorts were complete, cultures were grown at 30°C at 250 rpm 
overnight to recover isolated yeast. Serial dilutions of negative and positive sort cultures 
were plated on SD-CAA plates.  
The culture that resulted from the positive sort was pelleted and 4 mL of media 
removed. The pelleted cells and beads were resuspended in the remaining 1 mL of 
culture and transferred to a 2 mL microcentrifuge tube. The mixture was added to the 
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magnet to remove the beads. Recovered cells were transferred back to the original 
culture tube. Culture density was measured at OD600 and original library diversity 
calculated by back-calculating growth, assuming a doubling time of 4 h. 10X library 
diversity (after magnetic bead screening) was pelleted at high speed for 1 minute and 
resuspended in 5 mL of SG-CAA. Culture incubated at 20°C at 250 rpm for 24 hours for 
protein induction. 
Intermediate sorting was performed by pelleting 20x diversity of the induced 
population, washing in 1mL PBSA, pelleting at high speed for 1 min, and resuspending 
the cells in 1 mL of PBSA. Two negative sorts were performed sequentially - the first 
with 10uL of bare beads at 4°C for at least two hours rotating. Unbound cells from this 
first negative sort were then transferred to a new 2 mL microcentrifuge tube and once 
again incubated with 10 µL of bare beads at 4°C for at least two hours rotating. The 
bead and cell mixture was added to the magnet and unbound cells added to two tubes 
with washed ERK2-coated Dynabeads (as prepared previously). This positive sort was 
incubated at 4°C for at least two hours rotating. After incubation, mixture was washed 
on magnet with 1 mL PBSA to remove any non-bound yeast. Beads and cells were then 
resuspended in 5 mL of fresh SD-CAA. Serial dilutions of both negative sorts (washed 
as described for initial sort) and the positive sort were plated on SD-CAA plates.  As 
before, cultures were grown at 30°C at 250 rpm overnight.  
FACS of yeast surface displayed G4 library 
Protocols detailed here were based on those detailed in Chen et al., 2013. For 
sorting of fully displayed clones, 10X library diversity (post-
 57 
was washed with 1 mL of PBSA and resuspended in 100 µL of PBSA. Cells were 
labeled with 1 µL rabbit anti-c-myc (Sigma) for 1 hour at room temperature. Cells were 
washed with 1 mL of PBSA, pelleted at 3000xg for 1 min, and resuspended in 100 µL 
PBSA. Cells were then labeled with 10 µL of mouse anti-HA-FITC (Abcam) and 1 µL 
goat anti-rabbit AF647 for 1 hour on ice, maintaining a 10X excess of antibody:FN3. 
Estimating 105 FN3/yeast cell [116], for 107 cells in 100 µL, 2.5 µL of a 1mg/mL 
antibody stock is required. Cells were washed 3x in 1 mL PBSA and resuspended in 500 
µL for sorting. Single-labeled and unlabeled cells were prepared in parallel and used to 
set gates on BD FACSAria flow cytometer. Sorted cells were collected in 15 mL tubes 
into 2 mL of SD-CAA media and recovered in the same tube overnight at 30°C at 250 
rpm.  
  For sorting of binders, 10X library diversity (post-sorting of fully displayed 
clones) was washed with 1 mL of PBSA and resuspended in 100 µL of PBSA. Primary 
labeling was achieved by incubating cells with 1µL rabbit anti-c-myc (Sigma) and 
indicated concentration of biotinylated ERK2 (Round 3- 500 nM, Round 4 – 500 nM, 
Round 5- 100 nM) for 1 hour at room temperature. Cells were washed with 1 mL of 
PBSA, pelleted at high speed for 1 min, and resuspended in 100 µL of PBSA. Secondary 
labeling was achieved by incubating cells with Streptavidin-AF488 and goat anti-rabbit 
AF647 for 1 hour on ice. Cells were washed 3x in 1 mL PBSA and resuspended in 
PBSA for sorting. Incubation volumes usually ranged from 100 – 500 µL and varied 
based on the antigen (ERK2) concentration required and were optimized to ensure 10X 
excess antigen:FN3 and minimize antigen required. Single-labeled and unlabeled cells 
were prepared in parallel and used to set gates on BD FACSAria flow cytometer. Sorted 
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cells were collected in 15 mL tubes into 2 mL of SD-CAA media and recovered in the 
same tube overnight at 30°C at 250 rpm.  
Plasmid Isolation from Yeast 
Protocols detailed here were based on those detailed in Chen et al., 2013. 
Following isolation of full-length clones by FACS, 108  cells were pelleted at 300xg and 
plasmids isolated using Zymoprep Yeast Plasmid Miniprep Kit II (Zymo Research) with 
a slightly modified protocol. The pellet was resuspended in 200 µL Solution 1. 3 µL of 
Zymolase was added to the resuspended cells and incubated at 37°C for 1 hour. 200 µL 
of Solution was added with gentle mixing. Then 400 µL of Solution 3 was added and 
gently mixed. Samples were centrifuged at 12,000xg for 8 minutes. Supernatant was 
removed and centrifuged again at 12,000xg for 5 minutes. The cleared supernatant was 
transferred to an Epoch miniprep column. Spin column was centrifuged at 12,000xg for 
1 minute and the flow through discarded. Column was washed with 550 µL of PE buffer 
(Qiagen) and centrifuged at 12,000xg for 1 minute. Flow through was discarded and the 
column was centrifuged again to clear any remaining PE buffer. Plasmid DNA was 
eluted with 40 µL of ddH2O.  
Random mutagenesis of pCT-Con-FN3 library  
Zymoprepped plasmid DNA was subjected to random mutagenesis using the 
Random Mutagenesis Kit (Agilent) and primers detailed in Chen et al., 2013. The entire 
FN3 gene was targeted for low levels of mutagenesis and the three loops – BC, DE, and 
FG – were targeted for high levels of mutagenesis as detailed in the Random 
Mutagenesis Kit protocol. Mutagenized samples were run on a 1.5% agarose gel with 
DNA standards to quantify amount of amplification, and by extension level of 
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mutagenesis. Desired bands were purified by Qiagen DNA Gel Extraction Buffers and 
then further amplified with primers detailed in Chen et al., 2013 using standard Vent 
Polymerase conditions. Amplified DNA samples were then purified with Qiagen DNA 
PCR Clean-Up Buffers.  
 
Yeast library electroporation 
Protocols detailed here were based on those detailed in Chen et al., 2013. pCT-
Con-Gene vector was linearized by first digesting with NdeI overnight at 37°C, 
followed by digestion with PstI and BamHI. pCT-Con-Loop vector was linearized by 
first digesting with SmaI overnight at 37°C, followed by digestion with NcoI and NdeI. 
After fully digested, linearized plasmids were purified using Qiagen PCR Clean-Up 
Buffers.  
Protocols detailed in Benatuil et al., 2010 were used as a reference for the 
following yeast electroporation steps. EBY100 yeast cells were grown overnight in YPD 
at 225 rpm and 30°C. The next day, the EBY100 were subculture into 100 mL YPD at 
0.3 OD600. The subculture was grown at 30°C and 225 rpm until reaching OD600 = 1.6, 
when yeast cells were pelleted by centrifugation at 3000xg for 3 minutes. Cell pellet 
was washed twice with 50 mL ice-cold water and once with 50 mL ice-cold 
electroporation buffer (1M Sorbitol/1 mM CaCl2). The yeast were then resuspended in 
20 mL 0.1M LiAc/10 mM DTT in a culture flask and incubated for 30 minutes at 30°C 
with shaking at 225rpm. Then, cells were collected by centrifugation and washed with 
50 mL ice-cold electroporation buffer. Finally, the cells were resuspended in 100 to 200 
µL electroporation buffer to obtain a final volume of 1 mL – which is enough for two 
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electroporations of 400 µL each. 400 µL of prepared cells were added to 4 µg of 
linearized pCT-Con-Gene vector and 12 µg of mutagenized, amplified FN3 gene 
fragments in less than 50 µL. The cell and DNA mixture was then transfered to a pre-
chilled 2 mm electroporation cuvette and incubated for 5 minutes on ice. The remaining 
aliquot of electrocompetent cells were prepared with 4 µg of linearized pCT-Con-Loop 
vector and 12 µg of mutagenized, amplified FN3 loop fragments (BC, DE, and FG 
fragments combined)  Cells were electroporated at 2,500 V and 25 µF. Electroporated 
cells were transfered into 8 mL of 1:1 1M Sorbitol: YPD and incubated at 30°C with 
shaking at 225 rpm for 1 hour. Cells were centrifuged and resuspended in 250 mL SD-
CAA. 10-fold dilutions were plated onto SD-CAA plates and incubated at 30°C for two 
days to determine library size.  
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CHAPTER 4 – EFFECTIVE DELIVERY OF UBIQUIBODIES 
INTRODUCTION 
A major barrier for the therapeutic development of ubiquibodies is efficient 
intracellular delivery. Unfortunately, intracellular delivery of protein-based therapeutics 
represents a significant obstacle as most globular protein drugs do not spontaneously 
cross plasma membranes due to their relatively large size and biochemical properties 
[50]. Unlike smaller PROTACs, which can be designed for cell-permeability [118], 
ubiquibodies are relatively bulky proteins that do not effectively penetrate the cell 
membrane. To remedy this issue, we pursued two distinct therapeutic delivery strategies 
- protein delivery via native lytic peptides and mRNA delivery via polypeptide 
nanoplexes. 
To explore the option of protein-based delivery, we genetically fused the native 
IpaH9.8 cell-penetrating peptide (CPP), 2αH, to the N-terminus of our previously 
described GS2-IpaH9.8 ubiquibody. The resulting 2αH-GS2-IpaH9.8 ubiquibody 
elicited robust GFP degradation when expressed via plasmid transfection. As a purified 
protein, 2αH-GS2-IpaH9.8 demonstrated autonomous cellular penetration consistent 
with endosomal pathway uptake, but GFP degradation was not observed. 
More successfully, we also investigated the use of mRNA-based delivery in 
collaboration with the Hammond Lab at MIT. We implemented a bioinspired mRNA 
delivery strategy whereby mRNA encoding GS2-IpaH9.8 with an additional 3′-terminal 
polyadenosine (poly A) tail was stoichiometrically complexed with poly A binding 
proteins (PABPs), which served to improve mRNA stability and also stimulate mRNA 
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translation in eukaryotic cells [94]. The resulting ribonucleoproteins (RNPs) were 
stabilized with cationic polypeptides to protect the mRNA from degradation, enable its 
uptake by cells, and facilitate its endosomal escape. Importantly, these co-assembled 
nanoplexes delivered GS2-IpaH9.8 mRNA in a manner that caused efficient GFP 
silencing after introduction to cultured mammalian cells stably expressing GFP and after 
administration to transgenic mice expressing GFP ubiquitously.  
Results 
Delivery of proteins via native lytic peptides  
To investigate whether our IpaH9.8-based ubiquibodies could be engineered to 
autonomously translocate into mammalian cells, we first genetically fused the native 
cell-penetrating peptide 2αH from IpaH9.8 [90] to the N-terminus of  GS2-IpaH9.8. 
(Fig. 4.1a). The resulting ubiquibody 2αH-GS2-IpaH9.8 retained the domain 
architecture of the parental IpaH9.8 protein with the exception of the replacement of the 
native LRR domain with GS2, our GFP-specific FN3. 2αH-GS2-IpaH9.8 showed 
similarly robust EGFP degradation activity in HEK293T cells when expressed from our 
traditional mammalian expression plasmid (Fig. 4.1b).  
To evaluate autonomous cellular uptake, proteins were expressed and purified 
from E. coli, followed by conjugation to the fluorophore AlexaFluor-488 to facilitate 
quantification and visualization (Fig. 4.2a). 2αH-GS2-IpaH9.8 did show autonomous 
cellular entry into HEK293T cells as observed by flow cytometry and 
immunofluorescence (Fig. 4.2b-c). No cellular uptake was observed for any proteins 
when incubated at 4°C, corroborating previous reports that CPP-mediated uptake relies 
on endocytic processes [90]. It remains unclear, however, why GS2 and IpaH9.8dLRR, 
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which lack the 2αH peptide, would elicit cellular uptake.  
Although fluorescently labeled GS2-IpaH9.8 and 2αH-GS2-IpaH9.8 proteins 
showed robust entry into HEK293T cells, when unlabeled ubiquibodies were incubated 
with Hela EGFP cells, no EGFP degradation was observed (Fig. 4.3).  Many factors 
could be contributing to this lack of observable activity, including entrapment in 
intracellular compartments, rapid degradation in lysosome, formation of inactive dimers, 
insufficient intracellular concentration, and insufficient incubation time.  
Figure 4.1 2αH-GS2-IpaH9.8dLRR still retains degradation activity.   
(a) Linear representation of IpaH9.8, GS2-IpaH9.8, and 2αH-GS2-IpaH9.8. Numbers refer to 
amino acid positions from N terminus (N) to C terminus (C). The proteins are aligned vertically 
with the NEL domain of IpaH9.8. (b) Flow cytometric analysis of EGFP fluorescence activity 
in HEK293T cells transfected with plasmid pcDNA3-EGFP alone or co-transfected with 
pcDNA3-EGFP and a plasmid encoding GS2-IpaH9.8, GS2-IpaH9.8C337A or 2αH-GS2-IpaH9 as 
indicated. Data are geometric MFI normalized to geometric MFI measured for HEK293T cells 
expressing ERK2-EGFP alone.  
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Figure 4.2 Mammalian cell uptake of 2αH-GS2-IpaH9.8.  
(a) Fluorescently imaged SDS-PAGE gel of 5µg of AF-488 labeled proteins as 
indicated. (b) Flow cytometric analysis of HEK293T cells incubated with 400 nM of 
AF-488 labeled proteins for the indicated time and temperature. Data are represented as 
the geometric MFI.   
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Delivery of mRNA encoding GS2-IpaH9.8 enables proteome editing in mice  
From a therapeutic standpoint, one of the biggest challenges facing protein-based 
technologies such as ubiquibodies is intracellular delivery [50]. The Hammond group 
previously showed that co-assembled nanoplexes comprised of synthetic mRNA 
containing a poly A tail, PABPs, and biocompatible cationic polypeptides (Fig. 4.4) 
resulted in greatly enhanced mRNA expression in vitro and in mice [94]. Here, we 
hypothesized that delivery of GS2-IpaH9.8 mRNA/PABP nanoplexes to mammalian 
cells would result in significantly greater ubiquibody expression relative to mRNA 
Figure 4.3 Degradation activity of 2αH-GS2-IpaH9.8dLRR in Hela EGFP cells.  
Flow cytometric analysis of Hela EGFP cells incubated with 400 nM, 800 nM, or 1600 nM, 
as indicated by the triangles, of purified GS2-IpaH9.8 or 2αH-GS2-IpaH9.8 for 24 hours. 
Data are geometric MFI normalized to geometric MFI measured for HEK293T cells 
expressing EGFP alone 
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transfection alone by the same polyamine in HEK293T cells, thereby leading to potent 
protein degradation. To test this hypothesis, we first evaluated GS2-IpaH9.8 
mRNA/PABP nanoplex delivery in vitro by quantifying the degradation of d2EGFP, a 
destabilized GFP variant that was expressed as a stable transgene in HEK293T cells. As 
expected, only when the cationic nanoplexes contained the active, target-specific GS2-
IpaH9.8 mRNA and PABP was robust d2EGFP degradation achieved (Fig. 4.5). All 
other controls including catalytically inactive GS2-IpaH9.8C337A mRNA/PABP 
nanoplexes, non-specific AS15-IpaH9.8 nanoplexes, and naked GS2-IpaH9.8 mRNA 
that was delivered without PABPs showed little to no silencing activity (Fig. 4.5). At 24 
hours post-treatment, HEK293Td2EGFP cells receiving GS2-IpaH9.8 mRNA/PABP 
nanoplexes exhibited an 85% decrease in fluorescence activity, which was directly 
comparable to the knockdown activity achieved following DNA transfection seen 
above.  
Figure 4.4 Schematic of polyamine -mediated stoichiometric assembly of 
ribonucleoproteins for enhanced mRNA delivery.  
Following internalization in cells (grey circle), nanoplex disassembly results in the release 
of mRNA/PABP that is either degraded or translated to produce ubiquibody proteins. 
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Encouraged by these results, we next evaluated ubiquibody nanoplex-mediated 
delivery and silencing activity in vivo. Transgenic UBI-GFP/BL6 mice, which 
constitutively express EGFP in all tissues [119], were given subcutaneous injections of 
GS2-IpaH9.8 mRNA/PABP nanoplexes in ears. Note that although this mouse strain 
ubiquitously expresses EGFP, fluorescence is absorbed and undetectable in areas that 
are covered by hairs. Fluorescent imaging at 24 hours post-injection revealed that EGFP 
fluorescence in the left ears, which received GS2-IpaH9.8 mRNA/PABP nanoplex 
injections, was robustly ablated with a 70% decrease in ear fluorescence (Fig. 4.6a and 
b). In stark contrast, fluorescence in the right ears, which received either catalytically 
inactive GS2-IpaH9.8C337A or non-specific AS15-IpaH9.8 nanoplex injections, was 
unaffected (Fig. 4.5a and b). Importantly, these results set the stage for therapeutic 
delivery of ubiquibodies as a viable strategy to post-translationally silence aberrantly 
expressed proteins in cancer and other  
Figure 4.5 In vitro nanoplex delivery of ubiquibody mRNA.  
Flow cytometric quantification of EGFP fluorescence activity in HEK293Td2EGFP cells 
incubated with:  mRNA encoding GS2-IpaH9.8, GS2-IpaH9.8C337A, or AS15-IpaH9.8; or 
with nanoplexes comprised of the same mRNAs formulated with PABP and TEP (N4) 
polyamine (mRNA:PABP weight ratio = 1:5). Measurements were taken at 24, 48, and 72 
h post delivery. Data are expressed as the mean ± S.D. of biological triplicates (three 
separately treated wells). p values were determined by paired sample t-test. 
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Figure 4.6 Proteome editing in mice via nanoplex delivery of ubiquibody mRNA.  
(a) Epifluorescence imaging of UBC-GFP mice at 0 h (top) and 24 h (bottom) after ear 
injection of nanoplexes containing mRNA encoding GS2-IpaH9.8 (solid white circle), 
GS2-IpaH9.8C337A (dashed white circle, top), or AS15-IpaH9.8 (dashed white circle, 
bottom). Numbers on the heat bar represent radiant efficiency (p/sec/cm2/sr)/(µW/cm2) (b) 
Quantification of GFP fluorescence in the ears of Ubi-GFP mice in (c). Data are reported 
as the mean radiant efficiency for each individual ear region (black circle) and the mean 
radiant efficiency (red bar) of each sample group (n = 6 for GS2-IpaH9.8, n = 3 for GS2-
IpaH9.8C337A, and n = 3 for AS15-IpaH9.8). p values were determined by paired sample t-
test.  
 
 
 70 
Discussion 
A major advantage of ubiquibodies is the ease with which they can be rapidly 
adapted to hit a variety of intracellular targets due to their recombinant, modular design, 
which capitalizes on a large, preexisting repertoire of synthetic binding proteins as well 
as systematic, genome-wide efforts to generate and validate protein binders de novo 
against the human proteome [26]. Because obtaining antibody mimetics that bind with 
high specificity and affinity to a target should be easier than obtaining small molecules 
with the same properties, making custom-designed PROTACs is likely to be a much 
more challenging task [50]. Nonetheless, PROTACs holds great promise as a 
therapeutic approach because it is based on small molecules that have strong odds of 
getting into cells. Indeed, impressive preclinical in vitro and in vivo data are propelling 
the development of clinically viable PROTACs as evidenced by the founding of Arvinas 
in 2013 and C4 Therapeutics in 2016. It should be pointed out, however, that traditional 
medicinal chemistry approaches will be needed to improve the oral bioavailability, 
pharmacokinetics, and absorption, distribution, metabolism, excretion and toxicity 
(ADMET) properties of PROTACs [35, 36]. Compared to PROTACs, intracellular 
delivery of ubiquibody-based therapeutics is a much bigger hurdle as most globular 
protein drugs do not spontaneously cross plasma membranes due to their relatively large 
size and biochemical properties [50].  
Cell penetrating peptides have emerged as a powerful tool for the delivery of 
proteins, nucleotides, and small molecules [120]. Furthermore, the identification of cell 
penetrating peptide sequences within bacterial effectors with known E3 ubiqutin ligase 
activity [88, 90, 121] made this an attractive strategy to pursue for the therapeutic 
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delivery of ubiquibodies. GS2-IpaH9.8 ubiquibody modified with the native cell-
penetrating peptide 2αH from the N-terminus of the parental IpaH9.8 protein did show 
autonomous cellular uptake as analyzed by flow cytometry, but no degradation activity 
was observed. The specificity of uptake is yet to be confirmed, however, as other 
IpaH9.8-based proteins lacking the 2αH peptide were also able to enter mammalian 
cells. Interestingly, when 2αH-GS2-IpaH9.8 was expressed via plasmid transfection, 
robust GFP degradation was observed. This result adds to the growing evidence of the 
flexibility of our ubiquibody design - not only can the binding and catalytic domains be 
easy interchanged, but the design is also amenable to protein fusion at its N-terminus. 
While this work failed to achieve delivery of active ubiquibodies with a cell-penetrating 
peptide, it is likely a result of insufficient experimental conditions and not an inherent 
limitation of the ubiquibody design.  
Another possible solution that we investigated here is the use of mRNA as a 
source of therapeutic gene product in vivo. In recent years, impediments to the use of 
mRNA, including its instability and immunogenicity, have been largely overcome 
through structural modifications, while issues related to delivery and protein expression 
profiles have been addressed through advances in nanotechnology and material science 
[122]. Here, we take advantage of our unique approach to create a first-in-kind 
therapeutic ubiquibody delivery strategy; this method involved a recently reported 
strategy of electrostatics to stabilize pre-formed protein-RNA complexes for delivery 
[94]. In terms of longevity of knockdown, this earlier study demonstrated that tail vein 
injection of nanoplexes formulated with luciferase mRNA resulted in the highest 
luciferase expression levels at 6 h post-injection, which remained statistically above 
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control at 24 h post-injection but significantly decayed to background after 48 h. While 
this previous work did not involve ubiquibodies directly, it does provide a sense for the 
longevity that might be possible using this delivery method. Here, synthetic mRNA 
encoding the GFP-directed GS2-IpaH9.8 chimera was co-assembled with PABPs and 
the assembled ribonucleoproteins were packaged into nanosized complexes using 
structurally defined polypeptides bearing cationic aminated side groups. The resulting 
nanoplexes achieved highly efficient silencing of GFP in vitro and in vivo, thereby 
demonstrating a new proteome editing paradigm and opening the door to clinical 
translation of ubiquibody -based therapeutics. 
Materials and Methods 
Cloning of 2aH constructs 
All plasmids used in this study are provided in Appendix C. To construct 
pcDNA3-2αH-GS2-IpaH9.8, a synthetic double-stranded gblock (IDT) encoding 
HindIII-Kozak- 2αH –BamHI-GS2-NheI was ligated into pcDNA3-GS2-IpaH9.8 
digested with HindII and NheI, to produce the final plasmid pcDNA3-2αH-GS2-
IpaH9.8. To construct pET28a-2αH-GS2-IpaH9.8 and pET28a-2αH-GS2-IpaH9.8C337A, 
the synthetic double-stranded gblock (IDT) encoding HindIII-NcoI/Kozak-2αH –
BamHI-GS2-NheI was digested with NcoI and NheI and ligated into pET28a resulting 
in the intermediate plasmid pET28a-2αH-GS2. IpaH9.8dLRR and IpaH9.8dlRRC337A 
were amplified with primers encoding 5’ NheI and 3’ Flag tag, His tag, and NotI 
sequences, followed by ligation into pET28a-2αH-GS2, resulting in the final plasmids 
pET28a-2αH-GS2-IpaH9.8 and pET28a-2αH-GS2-IpaH9.8C337A. All plasmids were 
verified by DNA sequencing at the Cornell Biotechnology Resource Center (BRC). 
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Purification of proteins 
GS2, IpaH9.8dLRR, IpaH9.8, GS2-IpaH9.8, and EGFP were purified as 
previously described (Chapter 2). 2αH-GS2-IpaH9.8 and 2αH-GS2-IpaH9.8C337A 
purified proteins were obtained by growing E. coli BL21(DE3) cells containing a 
pET28a-based plasmid encoding the desired protein in 200 mL of Luria-Bertani (LB) 
medium at 37°C. Expression was induced with 0.1 mM IPTG when the culture density 
(Abs600) reached 0.6-0.8 and growth continued for 6 h at 30°C. Cultures were harvested 
by centrifugation at 4,000xg for 30 min at 4°C. Cell pellets were stored at -20°C 
overnight. Thawed pellets were resuspended in 10 mL equilibration buffer (25 mM Tris-
HCl, pH 7.4, 500 mM NaCl and 20 mM imidazole) and lysed with a high-pressure 
homogenizer (Avestin Emulsi-Flex C5). The insoluble fraction was cleared by 
centrifugation at 12,000xg for 30 min at 4°C. His-tagged protein was purified by gravity 
flow using 500 µL HisPur Ni-NTA resin (ThermoFisher). The soluble fraction was 
passed through the resin, after which the resin was washed with 3 mL of wash buffer 
(25 mM Tris-HCl, pH 7.4, 500 mM NaCl and 50 mM imidazole). Protein was eluted 
with 1.5 mL elution buffer (25 mM Tris-HCl, pH 7.4, 500 mM NaCl and 250 mM 
imidazole). Purified fractions were desalted and concentrated (Pierce PES Protein 
Concentrators). GS2, IpaH9.8dLRR, IpaH9.8, GS2-IpaH9.8, and EGFP were purified as 
previously described (Chapter 2).  
Fluorophore conjugations 
Purified proteins were fluorescently labeled with Alexa Fluor 488 NHS Ester 
(ThermoFisher). Briefly, ~1 µmol of protein was incubated with 7.5 µmol of  Alexa 
Fluor-488 NHS Ester in PBS overnight at room temperature. Unreacted fluorophore was 
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removed using 10 MWCO desalting columns (Pierce). Degree of labeling was 
confirmed through quantification of A280 and A495 signals using ext. coefficient495 = 
71,000 mol/L cm-1. Typical degrees of labeling were between 0.5-1.  
Flow cytometric analysis 
HEK293T cells were maintained as described previously (Chapter 2). For 
plasmid-based degradation experiments, cells were passed into 12-well plates at 10,000 
cells/cm2. 16-24 h after seeding, cells were transiently transfected with 1 µg total DNA 
at a 1:2 ratio of DNA:jetPrime (Polyplus Transfection). Cells were transfected with 0.05 
µg of target, 0.25 µg of ubiquibody or control, and balanced with empty pcDNA3 
vector. Culture media was replaced 4-6 h post-transfection. Then, 24 h post-transfection, 
cells were harvested and resuspended in PBS for analysis using a BD FACSCalibur. 
FlowJo Version 10 was used to analyze samples by geometric mean fluorescence 
determined from 10,000 events.   
For cell uptake experiments, cells were passed into 12-well plates at 10,000 
cells/cm2 16-24 h after seeding, media was removed and 1 mL of fresh media containing 
the desired concentration of protein was added to the cells. After the desired incubation 
time, cells were harvested and washed with PBS. Immediately before analyzing on BD 
FACSCalibur, samples were diluted 1:1 in Trypan Blue to quench any proteins still 
externally associated with the cells.  
Synthesis and characterization of cationic polypeptides 
N4 (TEP) polyamines were synthesized as we described recently [94] according 
to a modified procedure of Uchida and coworkers [123]. Briefly, to a chilled solution of 
poly(β-benzyl-L-aspartate) in N-methyl-2-pyrrolidone (NMP) (Sigma) (2 mL) was 
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added dropwise with stirring 50 equivalents of tetraethylenepentamine (Sigma) diluted 
two-fold with NMP. After stirring for 2 h at 0°C, the pH was adjusted to 1 with 
dropwise addition while stirring of cold 6 N HCl. The resulting solution was dialyzed 
from a regenerated cellulose membrane bag (Spectrum Laboratories, 1 kDa MWCO) 
against 0.01 N HCl followed by distilled water, frozen, and lyophilized to give a white 
powder. Polyamines used in this study were characterized by 1H NMR spectra in 
deuterium oxide (Cambridge Isotope Laboratories) using a Bruker Avance 400 MHz 
NMR spectrometer at 25°C: 1H NMR (400 MHz, D2O) δ 4.72 (s, 1H), 3.64 – 3.39 (m, 
9H), 3.37 – 3.05 (m, 5H), 3.00 – 2.62 (m, 4H).  
Preparation of mRNA by in vitro transcription  
cDNA encoding ubiquibodies was cloned into pGEM4Z/GFP/A64 by replacing 
the GFP fragment with XbaI and NotI sites. Additionally, the human α-globin 3’ UTR 
sequence was placed between the cDNA and the poly A tail using NotI and EcoRI to 
improve mRNA translation. Linearization with SpeI, followed by in vitro transcription 
(IVT) with HiScribe™ T7 High Yield RNA Synthesis Kit (NEB), yielded a transcript 
containing 64 nucleotides of vector-derived sequence, the coding sequence, α-globin 3’ 
UTR, and 64 A residues. In a typical 20 µl reaction, the following nucleotides were 
prepared: ATP (10 mM), pseudo-UTP (10 mM), methyl-CTP (10 mM), GTP (2 mM), 
anti-reverse Cap analog (8 mM, NEB). RNA was purified by RNeasy purification kit 
(Qiagen, Hilden, Germany). RNA quality was confirmed by running a 1% agarose gel. 
Concentration was determined by Abs260.  
Nanoplex transfection.  
Polyamines were dissolved in 10 mM HEPES buffer (pH 7.4). For each well of a 
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96-well plate, 200 ng mRNA diluted in 5 µl OptiMEM (Thermo Fisher) was mixed with 
5 µl OptiMEM containing PABP (mRNA:PABP weight ratio = 1:5) at room temperature 
for 10 min. Afterwards, 5 µl OptiMEM containing polyamines was added and incubated 
at room temperature for 15 min prior to transfection into HEK293T stably expressing 
d2EGFP. Polyamines were adjusted to achieve 50 to 1 (N/P) ratio for transfection. 
EGFP expression was measured by BD FACSCelesta at different time points after 
transfection.  
Animal experiments  
Mouse care and experimental procedures were performed under pathogen-free 
conditions in accordance with established institutional guidelines and approved 
protocols from the MIT Division of Comparative Medicine. C57BL/6-Tg(UBC-
GFP)30Scha/J mice were purchased from Jackson Laboratory. 8-10 week-old mice were 
injected subcutaneously in ears with 5 µg mRNA and 25 µg PABP packaged with N4 
(TEP) polyamines in a volume of 25 µl OptiMEM under anesthesia. Fluorescent 
imaging was performed with a CCD camera mounted in a light-tight specimen box 
(Xenogen). The exposure time was 1 s. Imaging and quantification of signals were 
controlled by Living Image acquisition and analysis software (Xenogen). 
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CHAPTER 5 - APPROACHES TOWARDS SPATIOTEMPORAL CONTROL OF 
UBIQUIBODY ACTIVITY 
Introduction 
While intracellular delivery poses a major challenge to the therapeutic 
application of ubiquibodies – for which we demonstrated successful strategies in 
Chapter 4 – it is also desirable to move beyond the use of perpetually active 
ubiquibodies towards a ubiquibodies endowed with spatial and temporal control. 
Recently, several studies have reported the use of genetically encoded photoreceptors to 
create engineered protein chimeras that are normally inactive, but that can be 
specifically “turned-on” by an external stimulus such as blue-light [124].  
One light-gated strategy that has been used is the chimeric fusion of LOV 
domains. LOV domains are naturally found in plants, regulating a variety of 
photosynthetic processes [125]. LOV domains are members of the Per-Arnt-Sim (PAS) 
family, a class of signaling proteins, and as such adopt the canonical PAS domain fold 
[126]. They non-covalently bind a flavin nucleotide cofactor (FMN or FAD), but upon 
photoactivation, a covalent thioether bond is formed between the cofactor and a highly 
conserved cysteine residue on the LOV domain. This light absorption induces changes 
in and through the β -sheet of the LOV domain to the outer surface, where downstream 
effects depend on the specific LOV domain being used [126]. In a well-studied example, 
LOV2 from Avena sativa phototropin I (AsLOV2), a C-terminal amphipathic helix (Jα) 
undergoes significant light-induced conformational changes, while the LOV core 
experiences only small perturbations [127]. In the dark-state, the Jα helix interacts with 
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the β-sheet of the LOV core, but upon illumination, Jα undocks and unfolds, 
propagating signal to an effector domain [128]. The N-terminal A’α helix also exhibits 
light-induced unfolding, and triggers Jα undocking [129].  
Several reports have shown that LOV domains can successfully be used as input 
domains to create engineered photoreceptors with novel light-gated biological functions. 
Strickland et al. developed LOV-TAP, by fusing AsLOV2 N-terminally to TrpR, a 
bacterial transcription factor, such that they shared a continuous helix. In vitro 
experiments initially showed a 5-fold change in activity between the light and dark 
states, but further site-directed mutagenesis improved this activity to a 64-fold change. 
Similarly, Wu et al. fused AsLOV2 N-terminally to the GTPase RacI, resulting in a 10-
fold change in activity between the light and dark states. Moglich et al. successfully 
utilized a LOV domain from Bacillus subtilis YtvA to reprogram the histidine kinase 
FixL from an oxygen- to light-responsive protein, ultimately achieving 1000-fold higher 
activity in the light state. For each of the cases mentioned, library sizes were on the 
order of tens, and variants were screened manually.  
AsLOV2 has also been used to develop methods for light-gated protein 
degradation. Bonger et al. created a blue-light inducible degradation (B-LID) domain, 
by fusing a small four amino acid peptide degron to the C-terminus of the Jα helix of 
AsLOV2, which becomes exposed following blue-light induction. When fused to 
various fluorescent proteins, B-LID facilitated light-gated proteasome-mediated 
degradation in zebra fish [130]. Renicke et al. utilized an analogous strategy, 
demonstrating light-gated proteasome-mediated degradation in S. cerevisiae [131].  
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Several efforts have been described which employ genetically encoded 
dimerizers based on plant photoreceptors to engineer light-dependent protein-protein 
interactions [132-135]. A notable example from Kennedy et al., utilized light-inducible 
protein –interaction modules based on Arabidopsis thaliana cryptochrome 2 and CIB1. 
Importantly, this system requires no exogenous ligand and dimerizes upon blue-light 
exposure with subsecond time resolution and subcellular spatial resolution. 
Furthermore, recent work from the same group has optimized the CRY2-CIB1 system, 
producing smaller modules with reduced dark interaction [136]. This system has been 
used to optically regulate transcription [137], recombinase activity [136], signalling 
[138], and other cellular functions. 
Here, we present designs and preliminary characterization of proposed light-
induced ubiquibodies. A panel of chimeric fusions of AsLOV2 in between the GS2 
binding domain and IpaH9.8 catalytic domain of GS2-IpaH9.8 showed successful 
expression in mammalian cells. Further investigation of one fusion, GS2-AsLOV2-
IpaH9.8-R1, revealed that IpaH9.8dLRR retained its ubiquitination activity and 
AsLOV2 exhibited characteristic spectral properties. Split ubiquibody designs were also 
evaluated using two different sets of fusion partners – light-gated CIB1/CRY2 and 
chemically induced FKBP/FRB. A variety of chimeric fusion combinations were 
explored with highly variable expression in mammalian cells. In particular, 
IpaH9.8dLRR fusions showed very poor expression, which we hypothesized was due to 
auto-ubiquitination and subsequent proteasomal degradation. To investigate if reduced 
auto-ubiquitination ubiquibodies could be engineered , lysine mutants of GS2-IpaH9.8 
were generated and characterized for expression and degradation activity in mammalian 
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cells. All the individual lysine mutants showed robust degradation activity, but no 
significant improvement was observed for expression levels.  
Together, these results indicate that such chimeric fusion of light-gated or 
chemically inducible modules can be executed without disrupting the individual 
functions of the ubiquibody binding and catalytic domains. However, continued 
research needs to be performed to more thoroughly characterize the interactions of these 
domains on the overall ubiquibody function to fully realize light-gated targeted protein 
degradation.  
Results 
Engineering light-gated chimeric ubiquibodies 
Based on the success of AsLOV2 protein fusions in the literature, we 
hypothesized that a fusion between AsLOV2 and the C-terminal catalytic domain of 
IpaH9.8 could result in light-gated ubiquibody (Fig. 5.1). We designed and created a 
“register” of ubiquibody chimeras in which the AsLOV2 domain is sandwiched between 
the DBP and the IpaH9.8 catalytic domain. The C-terminal fusion between AsLOV2 and 
IpaH9.8 is varied by a single amino acid to attempt to effectively ratchet the proteins 
around each other, sampling all steric space (Fig. 5.2a). When expressed in HEK293T 
mammalian cells, all of the variants with the exception of GS2-AsLOV2-IpaH9.8-R3 
showed observable expression (Fig. 5.2b). Register variants R1, R2, R4, and R5 showed 
the strongest signal, but also resulted in very strong bands below the anticipated protein 
molecular weight, indicative of a degradation product. Comparatively, R9 and R10 had 
much lower expression levels, but also had a significantly lower proportion of the 
degradation product.   
 82 
 
 
 
 
 
 
Figure 5.1 Schematic of light-gated AsLOV2 ubiquibody chimeras.  
AsLOV2 fused C-terminal to DBP and N-terminal to IpaH9.8 catalytic domain can be 
stimulated by blue-light to reveal an active ubiquibody.  
Figure 5.2 Mammalian expression of AsLOV2-ubiquibody chimeras.  
(a) Detailed alignment of amino acid sequences of C-terminal AsLOV2 and N-terminal 
IpaH9.8 catalytic domain for the register of chimeric fusions. (b) Western blot analysis of 
HEK293T cell lysates transfected with indicated AsLOV2 chimeras expressed from 
pTriEx-3 vector. Blots were probed with antibodies specific for 6x-His (that detected tag 
on each ubiquibody). An equivalent amount of total protein was loaded in each lane. 
Molecular weight (MW) markers are indicated on left. Bands representing full-length 
protein are indicated with arrow.  
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AsLOV2 can be mutated to lock its conformation in the “open” or “closed” 
states [139]. To evaluate these light-gated ubiquibody designs without the added 
dynamic layer of light activation, we cloned “open” mutants of variants R1, R3, and R7 
and evaluated their ubiquitination activity in E. coli expressing a reconstituted 
ubiquitination pathway (Fig. 5.3). While all three variants expressed in this system, but 
presented strong degradation bands. The high-molecular weight smearing detected for 
all three variants in the α-HIS blot is indicative of auto-ubiquitination. Similar laddering 
was observed in the α-ubiquitin blot, which could be indicative of ubiquibody auto-
ubiquitination, but the low molecular weights also point to the generation of free poly-
ubiquitin chains [140]. These results confirm that all three “open” variants contained 
active IpaH9.8 catalytic domains with R1 exhibiting the strongest degree of auto-
ubiquitination, while R7 showed the strongest production of free poly-ubiquitin chains.   
Next, the variant R1 was purified and analyzed by spectroscopy to evaluate 
AsLOV2. R1 displayed two strong fluorescence peaks at ~500 and ~525 nm, which 
were identical to the characteristic fluorescence profile observed from AsLOV2 alone 
[141]. No absorbance was observed from the buffer control or the GS2-IpaH9.8, 
confirming that the absorbance profile was specific to the AsLOV2 domain in the R1 
protein.  
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Figure 5.3 E. coli ubiquitination assay of light-gated AsLOV2 ubiquibody chimeras.   
Western blot analysis of Rosetta(DE3) E. coli cell lysates co-transfected with AsLOV2 
chimeras expressed from pTriEx-3 vector, .pCDF Duet UbcH5α/Ube1, and pACYC Ubiquitin 
Blots were probed with antibodies specific for 6x-His (that detected tag on each ubiquibody). 
and poly-ubiquitin An equivalent amount of total protein was loaded in each lane. Molecular 
weight (MW) markers are indicated on left. Bands representing full-length ubiquibody protein 
are indicated with arrow.  
 
Figure 5.4 Fluorescence spectra of light-gated AsLOV2 ubiquibody fusion.  
Absorption spectra of purified GS2-AsLOV2-IpaH9.8-R1, purified GS2-IpaH9.8, or buffer 
only. Samples were excited at 450 nm and emission fluorescence measured at the indicated 
wavelengths.  
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Designs for inducible ubiquibodies via protein interacting pairs 
Another approach is to employ a split protein system in which the binding 
domain and catalytic domain are expressed separately and ubiquibody function is only 
achieved when the two halves are reassembled following an exogenous stimulus. 
Typically, the protein fragments are genetically fused to two known interacting proteins. 
We chose to look at two different systems: CRY2/CIB1 light-inducible pairing (Fig. 
5.3) and FKBP/FRB rapamycin-inducible pairing (Fig. 5.4).  
All CIB1/CRY2 fusions showed fairly equal expression in mammalian cells, but 
were not as well expressed as the GS2-IpaH9.8 ubiquibody (Fig. 5.3b). FRB/FKBP 
fusions had highly variable expression (Fig. 5.4b). FKBP-IpaH9.8dLRR and FKBP-
IpaH9.8dLRRC337A fusions expressed higher than GS2-IpaH9.8, but FRB-IpaH9.8dLRR 
was undetectable and FRB-GS2 was extremely low. These results highlight the 
important role of the fusion partner in moderating expression level. Across the two sets 
of designs, IpaH9.8dLRR chimeras had very low expression, potentially due to auto-
ubiquitination leading to proteasomal degradation.  
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Figure 5.5 Mammalian expression of light-induced split ubiquibody designs.  
Western blot analysis of HEK293T cell lysates-transfected with pcDNA3 plasmids encoding 
the indicated chimeras. Blots were probed with antibodies specific for 6x-His (that detected 
tag on each chimera). An equivalent amount of total protein was loaded in each lane. 
Molecular weight (MW) markers are indicated on left.  
 87 
 
 
 
Figure 5.6 Mammalian expression of chemically-induced split ubiquibody designs.  
Western blot analysis of HEK293T cell lysates-transfected with pcDNA3 plasmids encoding 
the indicated chimeras. Blots were probed with antibodies specific for 6x-His (that detected a 
tag on each chimera). An equivalent amount of total protein was loaded in each lane. 
Molecular weight (MW) markers are indicated on left.  
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Reducing IpaH9.8 ubiquibody auto-ubiquitination 
Previously, our lab had detailed the reduction in the auto-ubiquitination of the E3 
ubiquitin ligase CHIP through mutation of lysine residues [142]. Here, we wanted to 
investigate if GS2-IpaH9.8 could maintain its exquisite degradation activity after lysine 
mutagenesis. GS2 contains two lysines, the C-terminal catalytic domain of IpaH9.8 
contains nine (Fig. 5.4), and the recombinant Flag tag contains two. When single lysine 
mutants of GS2-IpaH9.8 were co-expressed in mammalian cells with EGFP, degradation 
activity equivalent to the parental GS2-IpaH9.8 ubiquibody was observed (Fig. 5.5a). 
These mutants cover every lysine except for IpaH9.8K350. When these same constructs 
were evaluated for their expression in HEK293T cells, most mutants showed equivalent 
expression to the parental GS2-IpaH9.8, although GS2K55A-IpaH9.8 appeared to have a 
significant increase.  
Figure 5.7 Crystal structure of IpaH9.8 highlighting lysine residues.  
Crystal structure of the C-terminal NEL domain of IpaH9.8 (PDB 3l3p). Lysine (red) and 
cysteine (green) residues are colored for visualization.  
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Figure 5.8 Characterization of GS2-IpaH9.8 lysine mutants in mammalian cells.  
(a) Flow cytometric quantification of EGFP fluorescence activity in HEK293T cells transfected with 
pcDNA3-EGFP alone or cotransfected with pcDNA3-EGFP and a plasmid encoding the indicated 
ubiquibody. Data are biological triplicates (three separately transfected wells) of the geometric MFI 
normalized to MFI measured for HEK293T cells expressing EGFP alone. Error bars represent standard 
deviation (SD) of the mean. *, p < 0.01 (compared to HEK293T cells expressing EGFP only). (b). 
Western blot analysis of HEK293T cell lysates-transfected with pcDNA3 plasmids encoding GS2-
IpaH9.8, GS2-IpaH9.8C337A, or GS2-IpaH9.8 with the indicated lysine mutation. Blots were probed 
with antibodies specific for GFP, 6x-His (that detected tag on each ubiquibody), and GAPDH as 
indicated. An equivalent amount of total protein was loaded in each lane as confirmed by 
immunoblotting with anti-GAPDH. Molecular weight (MW) markers are indicated on left. 
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Discussion 
Ubiquibodies are a powerful tool for the targeted degradation of protein targets 
in mammalian cells, and have ben shown to be effective when delivered as mRNA 
nanoplexes, highlighting their therapeutic potential. However, to reduce drug side 
effects, there has been a wide range of targeted drug delivery approaches developed 
[143]. However, another approach is to indiscriminately deliver therapeutic cargo, but 
employ light-based strategies for the activation only in the desired cells at a designated 
time [144].  
Many have reported spatial and temporal control of specific protein function 
through the chimeric fusion of light-gated protein domains. We have preliminary 
evidence that the two most characterized approaches – AsLOV2 fusion and CIB1/CRY2 
split protein fusion – are compatible with our ubiquibody technology. The use of a light-
gated split ubiquibody really leverages the modularity of the ubiquibody design, 
separating binding and catalytic activity. Unfortunately this also means delivering two 
separate proteins and balancing the different expression levels of each to maintain an 
effective stoichiometry within the cell.  
For this reason, the addition of the AsLOV2 light-gated domain to the 
ubiquibody design could be advantageous.  While the designs we presented here attempt 
to light-gate the catalytic activity of the IpaH9.8 NEL domain, one could also envision 
moving AsLOV2 to the N-terminus of the binding domain, in an attempt to light-gate 
binding, hopefully prevent recognition of the target, except in the presence of a light 
stimulus. One of the major challenges associated with light-responsive proteins is the 
toxicity and lack of tissue penetration of blue-light wavelengths.  
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We observed highly variable expression levels of all light-induced fusions, 
particularly with IpaH9.8 NEL domain fusions. IpaH9.8 naturally exhibits auto-
inhibitory functionality when its native LRR domain is not bound to substrate [145]. It 
is likely that the fusions explored here do not offer the same protection for the catalytic 
cysteine, leading to higher auto-ubiquitination and subsequent degradation. In a 
therapeutic context, this is a challenge as it necessitates the delivery of higher quantities 
of ubiquibody to achieve the necessary intracellular concentration. While a completely 
lysine-free GS2-IpaH9.8 mutant was not active, the single lysine mutants showed no 
negative impact to their activity. Thus, while more research must be done to investigate 
the effect on these mutations on the GS2-IpaH9.8 half-life, lysine modification provides 
another method that we can employ to tune improve ubiquibody function.   
Materials and Methods 
Strains and Plasmids 
All plasmids used in this study are provided in Appendix C. For creation of 
light-gated ubiquibodies, plasmid pTriEx-3-GS2 was created by PCR amplification of 
GS2 from pHFT2-GS2 [95] using primers that introduced N-terminal Kozak and C-
terminal 6x-His, and FLAG sequences followed by ligation into pTriEx-3 such that 
EcoRV and HindIII restriction sites were available downstream of GS2 for generating 
C-terminal fusions. The register of AsLOV2-IpaH9.8 fusions was created using overlap 
extension PCR which added N-terminal NheI site and C-terminal Flag and 6xHis tags 
and HindIII site. For the initial AsLOV2 amplification, the plasmid pBabe-CMV-puro-
Tet-mVenus-Lov obtained from Addgene (#22033) served as the template.  
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Split ubiquibodies were created by PCR amplification of CRY2 from 
CRY2(535,L348F)-mCherry (Addgene #75372), CIB1 from pmGFP-CIB1 (Addgene 
#28240), FRB from pCherry-FRB (Addgene #25920), and FKBP from CFP-FKBP 
(Addgene #20160) with primers that introduced either 5’ HindIII and Kozak sequences 
and 3’ EcoRV site for C-terminal fusions or 5’ EcoRV and 3’ XbaI sites for N-terminal 
fusions. All plasmids were verified by DNA sequencing at the Cornell Biotechnology 
Resource Center (BRC). 
Flow cytometry 
Cells were passed into 12-well plates at 10,000 cells/cm2. 16-24 h after seeding, 
cells were transiently transfected with 1 µg total DNA at a 1:2 ratio of DNA:jetPrime 
(Polyplus Transfection). Cells were transfected with 0.05 µg of target, 0.25 µg of 
ubiquibody or control, and balanced with empty pcDNA3 vector. Culture media was 
replaced 4-6 h post-transfection. Then, 24 h post-transfection, cells were harvested and 
resuspended in phosphate buffered saline (PBS) for analysis using a BD FACSCalibur 
or BD FACSAria Fusion. FlowJo Version 10 was used to analyze samples by geometric 
mean fluorescence determined from 10,000 events.   
Western blotting 
HEK293T cells were plated at 10,000 cells/cm2 and transfected as described 
above before lysis with RIPA lysis buffer (Thermo Fisher). MCF10A cells were plated 
at 20,000 cells/cm2 and induced with 0.2 µg/mL doxycycline for 24 h before lysis with 
cell lysis buffer. Lysates were separated on Any kD polyacrylamide gels (Bio-Rad) and 
transferred to PVDF membranes. α-HIS-HRP (Abcam), α-GAPDH (Millipore), and 
mouse anti-ubiquitin (Millipore, P4D1-A11) antibodies were diluted 1:5,000 and in TBST 
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+ 1% milk and incubated for 1 h at room temperature. Secondary antibody goat anti-
mouse IgG with HRP conjugation (Promega) was diluted at 1:2,500 and used as needed. 
E. coli ubiquitination pathway reconstitution 
pCDF Duet UbcH5a/Ube1 was obtained by Su et al., J. Immunol., 2006. 
Ubiquitin was cloned without any tags into the second MCS of pACYC, with the MCSI 
used for the designated E3. Targets were expressed from their own plasmid. The 
indicated plasmids were transformed into BL21(DE3) cells. Overnight cultures were 
subcultured into 5mL of media + antibiotics at 1:100 at 37°C. At OD600 = 0.5-0.8 
cultures were induced with a final IPTG concentration of 1 mM and incubated for 3 hrs 
at 37°C. 1 mL of each culture was harvested by centrifugation at 13,200xg for 20 min. at 
4°C. Supernatant was removed and pellets lysed with 200uL of BugBuster by rotating 
for 20 min. at room temperature. After centrifugation at 13,200xg for 20 min. at 4°C, 
the supernatant was collected as the soluble fraction and boiled with 2X SDS Loading 
Buffer for 15 min. at 100°C. Bradford Assay determined soluble fraction total protein 
quantity. Western Blots were loaded accordingly, normalizing for total protein content. 
Protein expression and purification 
Purified proteins were obtained by growing Rosetta(DE3) cells containing a 
pTriEx-3-based plasmid in 200 mL of Luria-Bertani (LB) medium supplemented with 
50 µg/mL Ampicillin and 25 µg/mL Chloramphenicol at 37°C. Expression was induced 
with 0.1 mM IPTG when the culture density (Abs600) reached 0.6-0.8 and growth 
continued for 6 h at 30°C. Cultures were harvested by centrifugation at 4,000xg for 30 
min at 4°C. Cell pellets were stored at -20°C overnight. Thawed pellets were 
resuspended in 10 mL equilibration buffer (25 mM Tris-HCl, pH 7.4, 500 mM NaCl and 
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20 mM imidazole) and lysed with a high-pressure homogenizer (Avestin Emulsi-Flex 
C5). The insoluble fraction was cleared by centrifugation at 12,000xg for 30 min at 4°C. 
His-tagged protein was purified by gravity flow using 500 µL HisPur Ni-NTA resin 
(ThermoFisher). The soluble fraction was passed through the resin, after which the resin 
was washed with 3 mL of wash buffer (25 mM Tris-HCl, pH 7.4, 500 mM NaCl and 50 
mM imidazole). Protein was eluted with 1.5 mL elution buffer (25 mM Tris-HCl, pH 
7.4, 500 mM NaCl and 250 mM imidazole). Purified fractions were desalted and 
concentrated (Pierce PES Protein Concentrators).  
Spectra 
Fluorescence spectra were obtained at an excitation wavelength of 450 nm using 
a TECAN Infinite M1000 Pro.   
Blue-light device 
A blue-light device was created following the instructions found in Support 
Protocol 1 in Tucker et al., 2015 [146].Twelve Blue (470 nm) Luxeon Reel LED on a 
SinkPAD-II 10 mm Square Base (SP-05-B4) and a 70 mm x 130 mm rectangular 20 mm 
High Alpha Heat Sink (2.1 °C/W) were ordered from luxeonstar.com. DFRobot 
DFR00009 LCD Shield for Arduino and Arduino Uno R3 Microcontroller A000066 
were ordered fro Amazon. Images of the blue light device can be found in Appendix B.  
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CHAPTER 6 - FUTURE DIRECTIONS 
Introduction 
Protein knockout has always been an attractive way to elucidate cellular 
functions and holds therapeutic potential for the elimination of disease-relevant proteins. 
Recently, there has been a growing interest in targeted protein degradation techniques 
due to their catalytic activity, which requires lower intracellular concentrations than 
binding-through-inhibition techniques and their protein-level specificity, which enables 
the discrimination of post-translationally modified proteins  
Our group has been developing ubiquibodies, which combine the catalytic 
ubiquitination activity of the mammalian E3 ubiquitin ligase CHIP and the specificity of 
designer binding proteins to eliminate protein targets from mammalian cells. In this 
work, we leveraged flow cytometry to rapidly screen a large variety of alternative E3 
ubiquitin ligases for ubiquibody activity, which led to the discovery of the potent 
bacterial IpaH9.8 E3 ubiquitin ligase catalytic domain. Fusion of IpaH9.8 to the GFP-
specific FN3 binding domain GS2- enabled the robust degradation of EGFP and EGFP-
tagged mammalian proteins in all subcellular compartments and from all expression 
modalities. Furthermore, IpaH9.8 ubiquibodies with new specificities were rapidly 
generated by swapping the GFP-specific binding domain with designer binding domains 
that recognized SHP2, KRas, and ERK2. We also successfully demonstrated proteome 
editing in mice through the delivery of ubiquibodies packaged as mRNA nanoplexes. 
Furthremore, we detailed preliminary designs for the endowment of ubiquibodies with 
light-gated control. These results demonstrate modularity of the ubiquibody design and 
the therapeutic potential of ubiquibodies. However, there are still many facets of 
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ubiquibody-mediated protein degradation that necessitate more investigation and 
engineering.  
Discussion 
Continued exploration of bacterial E3 ubiquitin ligases 
In this work, we analyzed eighteen bacterial E3 ubiquitin ligases for their ability 
to be engineered as GFP-specific ubiquibodies, which at the time of our work were all 
the bacterial E3 ligases with characterized binding and catalytic domains – necessary 
information their manipulation into ubiquibodies. The first bacterial E3 ubiquitin ligases 
was not identified until AvrPtoB in 2006 [147], therefore it is high likely that there are 
many more uncharacterized bacterial effectors that possess E3 ubiquitin ligase activity. 
Every E3 ubiquitin ligase is unique and could offer advantageous characteristics for 
future ubiquibodies. One could even envision adapting our flow cytometric based 
method for evaluating characterizing new ubiquibodies for the validation of purported 
new E3 ubiquitin ligases.   
Therapeutic delivery for endogenous target degradation  
Engineered degraders must be able to efficiently enter cells if they are to be used 
as therapeutics. Efforts to overcome the delivery challenge in the context of targeted 
protein degradation have primarily focused on viral delivery methods [53, 55, 56], 
although the work presented here demonstrated the potential of nanoplex-mediated 
delivery of synthetic mRNA encoding ubiquibodies to achieve highly efficient silencing 
in vitro and in vivo [63]. In another recent study, Hantschel and coworkers used a 
chimeric bacterial toxin to deliver ubiquibodies in cancer cells [62]. Although not yet 
demonstrated for protein-based degraders, a number of other strategies have been 
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described for internalizing intact proteins including the use of cationic lipids [148], cell-
penetrating peptides [149], covalent attachment of oligosaccharides [150], esterification 
[151], and polymeric nanoparticles [152]. Additionally, continued efforts will need to be 
made to demonstrate the efficacy of ubiquibodies against endogenous targets. While in 
this work we were able to target overexpressed mammalian proteins as FP fusions, 
endogenous protein degradation warrants substantial investigation into the necessary 
ubiquibody characteristics such as affinity, half-life, delivery method, and host-cell 
effects.  
Endowing ubiquibodies with spatiotemporal control 
In addition to the continued development of delivery methods that can achieve 
therapeutically relevant concentrations of protein into cells, more work will also be 
needed to deliver proteins in a tissue-specific manner with minimal off-target effects. 
This could be accomplished by generating stimuli-sensitive switches that effectively 
control degrader activity. Along these lines, Ostermeier and coworkers have described 
methods for creating enzyme-binding protein hybrids whose enzymatic activity is 
activated only in the presence of antigen [153]. Another option would be the creation of 
light-inducible switches, such as the designs described in this work that could be 
conditionally activated in precise areas of the body, preferably using longer wavelengths 
of light. Towards this goal, Taxis and coworkers developed a generic photosensitive 
degron combining the light-reactive LOV2 domain with the mODC PEST sequence that 
provided synthetic light control of protein stability [131]. Overall, to advance from the 
lab to the clinic, these and other protein engineering advancements will be crucial for 
the development of protein-based degraders against virtually any protein of interest that 
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can be delivered efficiently and specifically in the body for the selective removal of 
disease-associated proteins. 
Yeast surface display for development of new ubiquibodies 
An outstanding question regarding ubiquibody design remains - is there an ideal 
designer binding domain scaffold for use in ubiquibody fusions? Results in Chapter 3 
provide preliminary evidence that FN3s are more compatible than DARPins or scFvs 
and results from Chapter 2 comparing the degradation activity of EGFP by IpaH9.8 
fused to a panel of GFP-specific FN3s indicates there may be an advantage to higher 
affinity, but there is not enough data to draw a definitive comparison.  In this work, 
however, we demonstrated that yeast surface display could rapidly identify novel FN3 
binders that can be evaluated for efficacy as ubiquibody fusions (Chapter 3). Similarly, 
yeast surface display could be used to identify novel binders to the same target protein 
from the range of available binding scaffolds: scFv, FN3, DARPin, sso7d, vhh, and 
VLR. Isolated binders could then be evaluated for their ability to degrade that target as 
ubiquibody fusions to IpaH9.8 or any other E3 ubiquitin ligase catalytic domain. 
Successful and unsuccessful ubiquibodies could be analyzed for characteristics such as 
target affinity, binding epitope, expression level, and half-life to elucidate a set of 
design rules for more efficient ubiquibody development in the future.  
One could also envision the use of yeast surface display for the high-throughput 
characterization of the full-length ubiquibody, not just the binding domain. Directed 
evolution could be used to enhance the catalytic performance of the E3 domain or 
reprogram its affinity and/or selectivity for different E2 partners. For instance, Klevit 
and coworkers developed a high-throughput mutagenesis strategy to probe the 
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mechanism of E3-catalyzed transfer of ubiquitin from the E2 to the target protein [154]. 
By scoring the effect of nearly 100,000 mutations in an E3, they identified mutations 
that enhanced E3 activity both in vitro and in cellular degradation assays. This 
mutagenesis and screening approach not only uncovered activity-enhancing mutations 
but also helped to delineate the molecular basis of E3 ligase activity, which could be 
used in the future to rationally design even better catalysts. Finally, while ubiquibodies 
have focused exclusively on replacing the native substrate-binding domains (e.g., 3-
tetratricopeptide repeat (TPR) in human CHIP; LRR in S. flexneri IpaH9.8) of the E3 
with synthetic binding proteins, one could instead change the specificity of these 
domains through directed evolution, thereby obviating the need for their removal. In 
support of this concept, combinatorial libraries based on TPR and LRR scaffolds have 
been constructed, and following high-throughput screening variants with custom 
binding specificities and affinities were isolated [155, 156].  
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APPENDIX A – BACTERIAL E3 UBIQUITIN LIGASES 
 
E3 ubiquitin 
ligase 
Classification Organism Construction Ref.1 
AvrPtoB U-box Pseudomonas 
syringae 
AvrPtoB1-436 fused to N-terminus of GS2 [157] 
βTrCP F-box Homo sapiens βTrCP1-568 fused to N-terminus of GS2 with 
(GlySer)10 linker 
[51] 
CHIP U-box H. sapiens CHIP128-303 fused to C-terminus of GS2 [57] 
IpaH0722 NEL Shigella flexneri IpaH0722295-587 fused to C-terminus of GS2 [158] 
IpaH1.4 NEL S. flexneri IpaH1.4285-575 fused to C-terminus of GS2 [[158] 
IpaH2.5 NEL S. flexneri IpaH2.5292-570 fused to C-terminus of GS2 [158] 
IpaH4.5 NEL S. flexneri IpaH4.5296-574 fused to C-terminus of GS2 [158] 
IpaH7.8 NEL S. flexneri IpaH7.8274-565 fused to C-terminus of GS2 [158] 
IpaH9.8 NEL S. flexneri IpaH9.8254-545 fused to C-terminus of GS2 [159] 
LegAU13 F-box Legionella 
pneumophila 
LegAU131-50 fused to N-terminus of GS2 [160] 
LegU1 F-box L. pneumophila LegU11-56 fused to N-terminus of GS2   [160] 
LubX U-box L. pneumophila LubX1-215 fused to N-terminus of GS2 [161] 
NleG2-3 U-box Enterohemorrhagic 
Escherichia coli 
(EHEC) O157:H7 
NleG2-390-191 fused to C-terminus of GS2 [162] 
NleG5-1 U-box EHEC O157:H7 NleG5-1113-213 fused to C-terminus of GS2 [162] 
NleL HECT EHEC O157:H7 NleL371-782 fused to C-terminus of GS2 [163] 
SidC Unconventional L. pneumophila SidC1-542 fused to N-terminus of GS2 [75] 
Slmb F-box Drosophila Slmb199-510 fused to C-terminus of GS2 [59] 
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melanogaster 
SlrP NEL EHEC O157:H7 SlrP465-765 fused to N-terminus of GS2 [164] 
SopA HECT Salmonella 
typhimurium 
SopA370-782 fused to C-terminus of GS2 [165] 
SPOP F-box H. sapiens SPOP167-374 fused to C-terminus of GS2 [65] 
SspH1 NEL S. typhimurium SspH1404-701 fused to N-terminus of GS2 [166] 
SspH2 NEL S. typhimurium SspH2492-788 fused to C-terminus of GS2 [167] 
VHL SCF-like ECV H. sapiens VHL1-213 fused to N-terminus of GS2 [168] 
XopL Unconventional Xanthomonas 
campestris 
XopL474-660 fused to C-terminus of GS2 [92] 
Table A.1 Bacterial E3 ubiquitin ligases used in this study. 
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APPENDIX B – BLUE-LIGHT DEVICE IMAGES 
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APPENDIX C – STRAINS AND PLASMIDS 
 
Strain   
DH5α F- (Φ80ΔlacZDM15,) Δ(lacIZYA-argF)U169 recA1 endA1 
hsdR17(rk-,mk+) phoA supE44 λ- thi-1 gyrA96 relA1  
Laboratory stock 
BL21(DE3) F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) Laboratory stock 
Rosetta(DE3) F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) pRARE (CmR) Laboratory stock 
EBY100 MATa AGA1::GAL1AGA1::URA3 ura352 trp1 leu2-
delta200 his3delta200 pep4::HIS3 prbd1.6R can1 GAL 
Laboratory stock 
Cell line   
HEK293T  Laboratory stock 
HEK293T-EGFP HEK293T cells stably expressing EGFP This study 
HEK293T-ERK2-EGFP HEK293T cells stably expressing ERK2-EGFP This study 
HEK293T-EGFP-HRasG12V 
HEK293T cells stably expressing EGFP-HRasG12V This study 
HEK293T-d2EGFP HEK293T cells stably expressing d2EGFP This study 
HeLa H2B-EGFP HeLa cells stably expressing H2B-EGFP fusion [59] 
MCF-10A  Laboratory stock 
MCF-10A rtTA  Laboratory stock 
MCF-10A rtTA EGFP-
HRASG12V 
MCF-10A cells stably expressing EGFP-HRASG12V fusion 
and rtTA 
This study 
MCF-10A rtTA GS2-IpaH9.8 MCF-10A cells stably expressing GS2-IpaH9.8 fusion and 
rtTA 
This study 
MCF-10A rtTA EGFP-
HRASG12V + GS2-IpaH9.8 
MCF-10A cells stably expressing EGFP-HRASG12V fusion, 
GS2-IpaH9.8, and rtTA 
This study 
MCF-10A rtTA EGFP 
HRASG12V + GS2-IpaH9.8C337A 
MCF-10A cells stably expressing EGFP-HRASG12V fusion, 
GS2-IpaH9.8C337A, and rtTA 
This study 
   
Plasmid Relevant features Source 
pcDNA3 CMV promoter, AmpR Laboratory stock 
pCDH1-CMV-MCS-EF1α-Puro CMV promoter; PurR, AmpR Laboratory stock 
pET28a(+) T7lac promoter; KanR Novagen 
pET24d(+) T7lac promoter; KanR Novagen 
pTriEx-3 CMV promoter; T7 promoter; AmpR Novagen 
psPAX2 Lentiviral packaging vector; CMV promoter; AmpR Laboratory stock 
pMD2.G Lentiviral packaging vector; CMV promoter; AmpR Laboratory stock 
pPB TetOn Hygro Transposon vector; SV40 promoter; AmpR Laboratory stock  
Mammalian Cell Line Generation 
pLV rtTA-NeoR Tetracycline inducible reverse transcriptional transactivator; 
CMV promoter; EF1α promoter; NeoR; AmpR 
Laboratory stock 
pCMV-hyPBase PiggyBac transposase; CMV promoter; AmpR [169] 
pHIV-d2EGFP Lentiviral vector expressing d2EGFP EF-1α promoter, IRES; 
AmpR 
[170] 
pPB-GS2-IpaH9.8 GS2-IpaH9.8 with C-terminal Flag and 6x-His tags cloned in 
pPB TetOn Hygro; CMV promoter; SV40 promoter; AmpR 
This study 
pPB-GS2-IpaH9.8C337A GS2-IpaH9.8C337A with C-terminal Flag and 6x-His tags 
cloned in pPB TetOn Hygro; CMV promoter; SV40 
promoter; AmpR 
This study 
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pCDH1-ERK2-EGFP ERK2 fused to N-terminus of EGFP cloned in pCDH1-CMV-
MCS-EF1α-Puro; CMV promoter; PurR, AmpR 
This study 
pCDH1-EGFP EGFP cloned in pCDH1-CMV-MCS-EF1α-Puro; CMV 
promoter; PurR, AmpR 
This study 
pCDH1-EGFP-HRasG12V HRasG12V fused to C-terminus of EGFP cloned in pCDH1-
CMV-MCS-EF1α-Puro; CMV promoter; PurR, AmpR  
This study 
 
mRNA Production 
pGEM4Z/GFP/A64 In vitro transcription of GFP with 3’ 64 residue poly A tail; 
T7 promoter; AmpR 
[171] 
pGEM4Z/GS2-IpaH9.8/A64 In vitro transcription of GS2-IpaH9.8 with 3’ human globin 
UTR and 64 residue polyA tail; T7 promoter; AmpR 
This study 
pGEM4Z/GS2-IpaH9.8C337A/A64 In vitro transcription of GS2-IpaH9.8C337A with 3’ human 
globin UTR and 64 residue polyA tail; T7 promoter; AmpR 
This study 
pGEM4Z/AS15-IpaH9.8/A64 In vitro transcription of AS15-IpaH9.8 with 3’ human globin 
UTR and 64 residue polyA tail; T7 promoter; AmpR 
This study 
Bacterial Protein Expression 
pSPI02B-BirA-His BirA expressed with C-terminal 6xHis tag; Tac promoter; 
StrepR 
Laboratory stock 
pCDF Duet UbcH5α/Ube1 UBE2D1 expressed from MCS1 with N-terminal His tag; 
UBE1 expressed from MCS2 with C-terminal S-Tag; T7lac 
promoters; StrepR 
Laboratory stock 
pACYC Ubiquitin Ubiquitin expressed from MCS2; T7 promoter; CmR This study 
pETHis6MEK1 R4F+ERK2 pET-based expression of two proteins: constitutively active 
MEK1 and wild-type, His-tagged ERK2 
[172] 
pET28-EGFP EGFP with C-terminal 6x-His tag in pET28a(+); T7lac 
promoter; KanR 
This study 
pET28(+)-GS2 GS2 with C-terminal Flag and 6x-His tags in pET28a(+); 
T7lac promoter; KanR 
This study 
pET24d(+)-GS2-IpaH9.8 GS2 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags in pET24d(+); T7lac promoter; KanR 
This study 
pET24d(+)-IpaH9.8dLRR IpaH9.8 lacking LRR domain with C-terminal Flag and 6x-
His tags in pET24d(+); T7lac promoter; KanR 
This study 
pET24d(+)-IpaH9.8dLRR IpaH9.8 domain with C-terminal Flag and 6x-His tags in 
pET24d(+); T7lac promoter; KanR 
This study 
pET28(+)-2αH-GS2-IpaH9.8 2αH fused to GS2-IpaH9.8 lacking LRR domain with C-
terminal Flag and 6x-His tags in pET28a; T7lac promoter; 
KanR 
This study 
pET28(+)-2αH-GS2-
IpaH9.8C337A 
Same as pET28a(+)-2αH-GS2-IpaH9.8, but includes cysteine 
to alanine mutation C337A in IpaH9.8.  
This study 
pTriEX-3-GS2-IpaH9.8C337A GS2 fused to IpaH9.8 lacking LRR domain and containing 
Cys337Ala mutation in pTriEx-3; CMV promoter; T7 
promoter; AmpR 
This study 
Synthetic Binding Domains 
pHFT2-GS2 GS2 monobody in pHFT2 plasmid; T7 promoter, KanR [95] 
pHFT2-GS5 GS5 monobody in pHFT2 plasmid; T7 promoter, KanR [95] 
pHFT2-GL4 GL4 monobody in pHFT2 plasmid; T7 promoter, KanR [95] 
pHFT2-GL6 GL6 monobody in pHFT2 plasmid; T7 promoter, KanR [95] 
pGalAga-GL8 GL8 monobody in pGalAgaCamR; CamR  [95] 
 106 
pHFT2-AblSH2MB#AS15 AS15 monobody in pHFT2 plasmid; T7 promoter, KanR  [21]  
pHFT2-SHP2-NSa1 NSa1 monobody in pHFT2 plasmid; T7 promoter, KanR  [112]  
pHFT2-SHP2-NSa5 NSa5 monobody in pHFT2 plasmid; T7 promoter, KanR  [112]  
pHFT2-SHP2-CS3 CS3 monobody in pHFT2 plasmid; T7 promoter, KanR [112] 
pET24a(+)-RasInI RasInI with C-terminal GS linker, 6xHis, Avi, and Flag tags; 
T7lac promoter; KanR 
[113] 
pET24a(+)-RasInII RasInII with C-terminal GS linker, 6xHis, Avi, and Flag tags; 
T7lac promoter; KanR 
[113] 
pE-Sumo-R11.1.6 R11.1.6 with N-terminal 6xHis and SUMOpro tags; T7 
promoter; AmpR 
[114] 
Protein Degradation Targets 
pLK1-ERK2 ERK2 with N-terminal Avi and C-terminal 6xHis tags; AmpR Laboratory stock 
pHFT2-SHP2 Full-length SHP2 in pHFT2 plasmid; T7 promoter, KanR [112] 
pcDNA3-EGFP EGFP cloned in pcDNA3; CMV promoter, AmpR; Kozak This study 
mEmerald-C1 CMV promoter; KanR Laboratory stock 
mVenus-N1 CMV promoter; KanR Laboratory stock 
pcDNA3-mCerulean CMV promoter; Kozak; AmpR This study 
pcDNA3-CFP CMV promoter; Kozak; AmpR This study 
pcDNA3-sfGFP CMV promoter; Kozak; AmpR This study 
pcDH1-mCherry CMV promoter; EF1α promoter; PuroR; AmpR Laboratory stock 
mEmerald-α-actinin-19 α-actinin fused to N-terminus of mEmerald; CMV promoter; 
KanR 
Laboratory stock  
pcDNA3.1(-)-α-synuclein-EGFP α-synuclein fused to the N-terminus of EGFP cloned in 
pcDNA3.1; CMV promoter; AmpR 
[173] 
mEmerald-FAK-5 FAK fused to C-terminus of mEmerald; CMV promoter; 
KanR 
Laboratory stock 
pEGFP-C1 F-tractin-EGFP F-tractin fused to N-terminus of EGFP; CMV promoter; 
KanR 
Addgene #58473 
EGFR-mEmerald EGFR fused to N-terminus of mEmerald; CMV promoter; 
AmpR 
Laboratory stock 
pErbB2-EGFP ErbB2 fused to N-terminus of EGFP; CMV promoter; AmpR Addgene #39321 
pcDNA3-ERK2-EGFP ERK2 fused to EGFP in pcDNA3; CMV promoter; Kozak; 
AmpR 
This study 
pLV-pGK-H2B-EGFP H2B fused to C-terminus of EGFP; pGK promoter; AmpR Laboratory stock 
mEGFP-HRasG12V HRasG12V (constitutively active) fused to mEGFP cloned in 
pCI; CMV promoter; AmpR 
[174]; Addgene 
#18666 
mEmerald-Muc1-FL Muc1 fused to N-terminus of mEmerald; CMV promoter; 
KanR 
Laboratory stock 
pcDNA3-EGFP-NLS NLS sequence derived from C-terminus of SV40 fused to C-
terminus of EGFP and cloned in pcDNA3; CMV promoter; 
AmpR 
This study 
mEmerald-Paxillin-22 Paxillin fused to N-terminus of mEmerald; CMV promoter; 
KanR 
Laboratory stock 
pcDNA3-SHP2-EGFP SHP2 fused to C-terminus of EGFP; CMV promoter; AmpR This study 
mEmerald-Vinculin-23 Vinculin fused to C-terminus of mEmerald; CMV promoter; 
KanR 
Laboratory stock 
pcDNA3-EGFP-KRas KRas fused to C-terminus of mEmerald; CMV promoter; 
AmpR 
This study 
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pcDNA3-EGFP-KRasG12C KRasG12C fused to C-terminus of mEmerald; CMV promoter; 
AmpR 
This study 
pcDNA3-EGFP-KRasG12D KRasG12D fused to C-terminus of mEmerald; CMV promoter; 
AmpR 
This study 
pcDNA3-EGFP-KRasG12V KRasG12V fused to C-terminus of mEmerald; CMV promoter; 
AmpR 
This study 
IpaH GFP-specific Ubiquibodies 
pcDNA3-HF-GS2  GS2 with N-terminal Kozak, Flag and 6xHis tags,and BamHI 
and EcoRI sites; CMV promoter; AmpR 
This study 
pcDNA3-GS2-FH GS2 with C-terminal NheI and SbfI sites, Flag tag, and 6xHis 
tag; CMV promoter; AmpR.  
This study 
pcDNA3-GS2-IpaH9.8 GS2 fused to Shigella flexneri IpaH9.8 lacking LRR domain 
(IpaH9.8ΔLRR) with C-terminal Flag and 6x-His tags cloned 
in pcDNA3; CMV promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-IpaH9.8C337A pcDNA3-GS2-IpaH9.8 containing Cys337Ala substitution This study 
pcDNA3-GS2-IpaH1.4 GS2 fused to S. flexneri IpaH1.4 lacking LRR domain with 
C-terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-IpaH2.5 GS2 fused to S. flexneri IpaH2.5 lacking LRR domain with 
C-terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-IpaH4.5 GS2 fused to S. flexneri IpaH4.5 lacking LRR domain with 
C-terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-IpaH7.8 GS2 fused to S. flexneri IpaH7.8 lacking LRR domain with 
C-terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-IpaH0722 GS2 fused to S. flexneri IpaH0722 lacking LRR domain with 
C-terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-GS5-IpaH9.8 GS5 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-GL4-IpaH9.8 GL4 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-GL6-IpaH9.8 GL6 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-GL8-IpaH9.8 GL8 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-vhhGFP4-IpaH9.8 vhhGFP4 fused to IpaH9.8 lacking LRR domain with C-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-2αH-GS2-IpaH9.8 pcDNA3-GS2-IpaH9.8 with N-terminal 2αH sequence.  This study 
pcDNA3-GS2-IpaH9.8K8A Same as pcDNA3-GS2-IpaH9.8 but includes K8A mutation 
in GS2 protein.  
This study 
pcDNA3-GS2-IpaH9.8K55A Same as pcDNA3-GS2-IpaH9.8 but includes K55A mutation This study 
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in GS2 protein.  
pcDNA3-GS2-IpaH9.8K266A Same as pcDNA3-GS2-IpaH9.8 but includes K266A 
mutation in IpaH9.8 protein.  
This study 
pcDNA3-GS2-IpaH9.8K315A Same as pcDNA3-GS2-IpaH9.8 but includes K315A 
mutation in IpaH9.8 protein.  
This study 
pcDNA3-GS2-IpaH9.8K389A Same as pcDNA3-GS2-IpaH9.8 but includes K389A 
mutation in IpaH9.8 protein.  
This study 
pcDNA3-GS2-IpaH9.8K412A Same as pcDNA3-GS2-IpaH9.8 but includes K412A 
mutation in IpaH9.8 protein.  
This study 
pcDNA3-GS2-IpaH9.8K420A Same as pcDNA3-GS2-IpaH9.8 but includes K420A 
mutation in IpaH9.8 protein.  
This study 
pcDNA3-GS2-IpaH9.8K465A Same as pcDNA3-GS2-IpaH9.8 but includes K465A 
mutation in IpaH9.8 protein.  
This study 
pcDNA3-GS2-IpaH9.8K479A Same as pcDNA3-GS2-IpaH9.8 but includes K479A 
mutation in IpaH9.8 protein.  
This study 
pcDNA3-GS2-IpaH9.8K496A Same as pcDNA3-GS2-IpaH9.8 but includes K496A 
mutation in IpaH9.8 protein.  
This study 
pcDNA3-GS2-IpaH9.8-H Same as pcDNA3-GS2-IpaH9.8 but lacks C-terminal Flag 
tag.  
This study 
Other GFP-specific Ubiquibodies 
pcDNA3-flag-βTrCP-10GS-
scFv13R4 
 
βTrCP expressed with N-terminal Flag tag and C-terminal 
GS linker and scFv13R4 fusion; CMV promoter, AmpR 
Laboratory stock 
pcDNA3-R4-CHIPdTPR scFv13-R4 fused to CHIP lacking TPR domain with C-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
[57] 
pcDNA3_NSlmb-vhhGFP4 vhhGFP4 fused to F-box domain from Drosophila 
melanogaster Slmb cloned in pcDNA3; CMV promoter, 
AmpR 
[59]; Addgene 
#35579 
pcDNA3-GS2-AvrPtoB GS2 fused to Pseudomonas syringae AvrPtoB lacking N-
terminal domain with C-terminal Flag and 6x-His tags cloned 
in pcDNA3; CMV promoter; Kozak; AmpR 
This study 
pcDNA3-LegAU13-GS2 GS2 fused to L. pneumophila LegAU13 F-box with N-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-LegU1-GS2 GS2 fused to L. pneumophila LegU1 F-box with N-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-LubX-GS2 GS2 fused to Legionella pneumophila LubX lacking CTD 
domain with N-terminal Flag and 6x-His tags cloned in 
pcDNA3; CMV promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-NleG2-3 GS2 fused to EHEC O157:H7 NleG2-3 lacking N-terminal 
domain with C-terminal Flag and 6x-His tags cloned in 
pcDNA3; CMV promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-NleG5-1 GS2 fused to EHEC O157:H7 NleG5-1 lacking N-terminal 
domain with C-terminal Flag and 6x-His tags cloned in 
pcDNA3; CMV promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-NleL GS2 fused to EHEC O157:H7 NleL lacking β-helix domain 
with C-terminal Flag and 6x-His tags cloned in pcDNA3; 
This study 
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CMV promoter; Kozak; AmpR 
pcDNA3-SidC-GS2 GS2 fused to L. pneumophila SidC lacking N-terminal 
domain with N-terminal Flag and 6x-His tags cloned in 
pcDNA3; CMV promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-SlrP GS2 fused to Enterohemorrhagic Escherichia coli (EHEC) 
O157:H7 SlrP lacking LRR domain with C-terminal Flag and 
6x-His tags cloned in pcDNA3; CMV promoter; Kozak; 
AmpR 
This study 
pcDNA3-GS2-SopA GS2 fused to S. typhimurium SopA lacking β-helix domain 
with C-terminal Flag and 6x-His tags cloned in pcDNA3; 
CMV promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-SspH1 GS2 fused to Salmonella typhimurium SspH1 lacking LRR 
domain with C-terminal Flag and 6x-His tags cloned in 
pcDNA3; CMV promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-SspH2 GS2 fused to S. typhimurium SspH2 lacking LRR domain 
with C-terminal Flag and 6x-His tags cloned in pcDNA3; 
CMV promoter; Kozak; AmpR 
This study 
pcDNA3-GS2-XopL GS2 fused to Xanthomonas campestris XopL lacking LRR 
domain with C-terminal Flag and 6x-His tags cloned in 
pcDNA3; CMV promoter; Kozak; AmpR 
This study 
pcDNA-βTrCP-GS2 GS2 fused to full length H. sapiens βTrCP with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-GS2-CHIPdTPR GS2 cloned in place of scFvR4 in pcDNA3-R4-CHIPΔTPR; 
CMV promoter; Kozak; AmpR 
This study 
pcDNA3-Slmb-GS2 GS2 cloned in place of vhhGFP4 in pcDNA3-NSlmb-
vhhGFP4; CMV promoter; Kozak; AmpR 
This study  
pcDNA3-GS2-SPOP GS2 fused to Homo sapiens SPOP F-box with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-VHL-GS2 GS2 fused to H. sapiens VHL F-box with N-terminal Flag 
and 6x-His tags cloned in pcDNA3; CMV promoter; Kozak; 
AmpR 
This study 
Ubiquibodies with disease-relevant specificity 
pcDNA3-AS15-IpaH9.8 AS15 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-NSa1-IpaH9.8 NSa1 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-NSa5-IpaH9.8 NSa5 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-CS3-IpaH9.8 CS3 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-NSa5-IpaH9.8C337A NSa5 fused to IpaH9.8C337A lacking LRR domain with C-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
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pcDNA3-RasInI-IpaH9.8 RasInII fused to IpaH9.8 lacking LRR domain with C-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-RasInII-IpaH9.8C337A RasInII fused to IpaH9.8C337A lacking LRR domain with C-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-RasInII-IpaH9.8 RasInII fused to IpaH9.8 lacking LRR domain with C-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-E40-IpaH9.8 E40 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-pE59-IpaH9.8 pE59 fused to IpaH9.8 lacking LRR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-EpE82-IpaH9.8 EpE82 fused to IpaH9.8 lacking LRR domain with C-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-EpE89-IpaH9.8 EpE89 fused to IpaH9.8 lacking LRR domain with C-
terminal Flag and 6x-His tags cloned in pcDNA3; CMV 
promoter; Kozak; AmpR 
This study 
pcDNA3-E40-CHIP E40 fused to CHIP lacking TPR domain with C-terminal Flag 
and 6x-His tags cloned in pcDNA3; CMV promoter; Kozak; 
AmpR 
This study 
pcDNA3-pE59-CHIP pE59 fused to CHIP lacking TPR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-EpE82-CHIP EpE82 fused to CHIP lacking TPR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
pcDNA3-EpE89-CHIP EpE89 fused to CHIP lacking TPR domain with C-terminal 
Flag and 6x-His tags cloned in pcDNA3; CMV promoter; 
Kozak; AmpR 
This study 
Inducible Ubiquibodies 
pBabe-CMV-puro-Tet-mVenus-
Lov 
AsLOV2 fused to the C-terminus of mVenus for mammalian 
expression; TetCMV promoter; AmpR 
Addgene (#22033) 
CRY2(535,L348F)-mCherry CRY2 (585 amino acid truncation) fused to N-terminus of 
mCherry for mammalian expression; CMV promoter; KanR 
Addgene (#75372) 
pmCIB1(dNLS)-pmGFP CIB1 lacking NLS fused to the N-terminus of pmGFP; CMV 
promoter; KanR 
Addgene (#28240) 
pCherry-FRB FRB fused to C-terminus of mCherry for mammalian 
expression; CMV promoter; KanR 
Addgene (#25920) 
CFP-FKBP FKBP fused to the C-terminus of CFP for mammalian 
expression; CMV promoter; KanR 
Addgene (#20160) 
pTriEx-3-GS2-AsLOV2 -R1-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
1 position; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-GS2-AsLOV2 –R2-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
2 position; CMV promoter; T7 promoter;  AmpR 
This study 
pTriEx-3-GS2-AsLOV2 –R3- GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register This study 
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IpaH9.8 3 position; CMV promoter; T7 promoter; AmpR 
pTriEx-3-GS2-AsLOV2 –R4-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
4 position; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-GS2-AsLOV2 –R5-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
5 position; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-GS2-AsLOV2 –R6-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
6 position; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-GS2-AsLOV2 –R7-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
7 position; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-GS2-AsLOV2 –R8-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
8 position; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-GS2-AsLOV2 –R9-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
9 position; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-GS2-AsLOV2 –R10-
IpaH9.8 
GS2-IpaH9.8 ubiquibody with AsLOV2 insertion in Register 
10 position; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-CRY2-IpaH9.8dlRR IpaH9.8dLRR expressed with C-terminal Flag and 6xHIS 
tags as a C-terminal fusion to CRY2; CMV promoter; T7 
promoter; AmpR 
This study 
pTriEx-3-CRY2-
IpaH9.8dlRRC337A 
IpaH9.8dLRRC337A expressed with C-terminal Flag and 
6xHIS tags as a C-terminal fusion to CRY2; CMV promoter; 
T7 promoter; AmpR 
This study 
pTriEx-3-CRY2-CHIPdTPR CHIPdTPR expressed with C-terminal Flag and 6xHIS tags 
as a C-terminal fusion to CRY2; CMV promoter; T7 
promoter; AmpR 
This study 
pTriEx-3-CRY2-GS2 GS2 with C-terminal Flag and 6xHIS tags expressed as a C-
terminal fusion to CRY2; CMV promoter; T7 promoter; 
AmpR 
This study 
pTriEx-3-CIB1-IpaH9.8dlRR IpaH9.8dLRR expressed with C-terminal Flag and 6xHIS 
tags as a C-terminal fusion to CIB1; CMV promoter; T7 
promoter; AmpR 
This study 
pTriEx-3-FRB-IpaH9.8dLRR IpaH9.8dLRR expressed with C-terminal Flag and 6xHIS 
tags as a C-terminal fusion to FRB; CMV promoter; T7 
promoter; AmpR 
This study 
pTriEx-3-FRB-
IpaH9.8dlRRC337A 
IpaH9.8dLRRC337A expressed with C-terminal Flag and 
6xHIS tags as a C-terminal fusion to FRB; CMV promoter; 
T7 promoter; AmpR 
This study 
pTriEx-3-FRB-GS2 GS2 with C-terminal Flag and 6xHIS tags expressed as a C-
terminal fusion to FRB; CMV promoter; T7 promoter; AmpR 
This study 
pTriEx-3-FKBP-IpaH9.8dLRR IpaH9.8dLRR expressed with C-terminal Flag and 6xHIS 
tags as a C-terminal fusion to FKBP; CMV promoter; T7 
promoter; AmpR 
This study 
pTriEx-3-FKBP-
IpaH9.8dlRRC337A 
IpaH9.8dLRRC337A expressed with C-terminal Flag and 
6xHIS tags as a C-terminal fusion to FKBP; CMV promoter; 
T7 promoter; AmpR 
This study 
pTriEx-3-FKBP-GS2 GS2 with C-terminal Flag and 6xHIS tags expressed as a C-
terminal fusion to FKBP; CMV promoter; T7 promoter; 
AmpR 
This study 
Yeast Surface Display 
pCT-Con-G4 G4 FN3 Library expressed as AGA2 fusion; Gal1-10 Laboratory stock. 
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promoter; Trp(+); AmpR 
pCT-FN3-Gene pCT-Con variant used for homologous recombination cloning 
containing HA and c-myc tags flanking PstI, NdeI, and 
BamHI sites; Trp(+); AmpR 
Laboratory stock 
pCT-FN3-Loop pCT-Con variant used for homologous recombination cloning 
containing FN3 gene, with DNA between BC and FG loop 
replaced by NcoI, SmaI, and NdeI sites; Trp(+); AmpR 
Laboratory stock 
Table C.1 Strains, cell lines, and plasmids used in this study. 
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